{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:54:48Z","timestamp":1794491688667,"version":"4.9.1"},"reference-count":362,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2019,7,25]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Obsessive-compulsive disorder (OCD) is associated with affective and cognitive symptoms causing personal distress and reduced global functioning. These have considerable societal costs due to healthcare service utilization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Our aim was to assess the efficacy of pharmacological interventions in OCD and clinical guidelines, providing a comprehensive overview of this field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We searched the PubMed database for papers dealing with drug treatment of OCD, with a specific focus on clinical guidelines, treatments with antidepressants, antipsychotics, mood stabilizers, off-label medications, and pharmacogenomics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Prolonged administration of selective serotonin reuptake inhibitors (SSRIs) is most effective. Better results can be obtained with a SSRI combined with cognitive behavioral therapy (CBT) or the similarly oriented exposure and response prevention (ERP). Refractory OCD could be treated with different strategies, including a switch to another SSRI or clomipramine, or augmentation with an atypical antipsychotic. The addition of medications other than antipsychotics or intravenous antidepressant administration needs further investigation, as the evidence is inconsistent. Pharmacogenomics and personalization of therapy could reduce treatment resistance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>SSRI\/clomipramine in combination with CBT\/ERP is associated with the optimal response compared to each treatment alone or to other treatments. New strategies for refractory OCD are needed. The role of pharmacogenomics could become preponderant in the coming years.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1570159x16666180813155017","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T09:20:13Z","timestamp":1535361613000},"page":"710-736","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)"],"prefix":"10.2174","volume":"17","author":[{"given":"Antonio","family":"Del Casale","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Sorice","sequence":"additional","affiliation":[{"name":"Residency School in Psychiatry, Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Padovano","sequence":"additional","affiliation":[{"name":"Residency School in Psychiatry, Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Simmaco","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ferracuti","sequence":"additional","affiliation":[{"name":"Department of Human Neuroscience, Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorian A.","family":"Lamis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Rapinesi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sani","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Girardi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios D.","family":"Kotzalidis","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health, and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Unit of Psychiatry, Sant\u00e2\ufffd\ufffdAndrea University Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","year":"2013","unstructured":". Diagnostic and Statistical Manual of Mental Disorders (DSM-5), ,American Psychiatric Association, 2013, 75,, 606-,","journal-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5)"},{"key":"ref=2","first-page":"5","volume":"55","author":"Rasmussen S.A.","year":"1994","unstructured":"Rasmussen SA, Eisen JL. J Clin Psychiatry, The epidemiology and differential diagnosis of obsessive compulsive disorder.,, 1994, 55,, 5-10,[PMID: 7961532].","journal-title":"J Clin Psychiatry"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"Ruscio A.M.","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC. Mol Psychiatry, The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication.,, 2010, 15,, 53-63,[http:\/\/dx.doi.org\/10.1038\/mp.2008.94]. [PMID: 18725912].","journal-title":"Mol Psychiatry"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","volume":"62","author":"Kessler R.C.","year":"2005","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Arch Gen Psychiatry, Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.,, 2005, 62,, 593-602,[http:\/\/dx.doi. org\/10.1001\/archpsyc.62.6.593]. [PMID: 15939837].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3109\/10673229809000309","volume":"5","author":"Geller D.A.","year":"1998","unstructured":"Geller DA, Biederman J, Jones J, Shapiro S, Schwartz S, Park KS. Harv Rev Psychiatry, Obsessive-compulsive disorder in children and adolescents: a review.,, 1998, 5,, 260-273,[http:\/\/dx.doi.org\/10.3109\/10673229809000309]. [PMID: 9493948].","journal-title":"Harv Rev Psychiatry"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.psc.2006.02.012","volume":"29","author":"Geller D.A.","year":"2006","unstructured":"Geller DA. Psychiatr Clin North Am, Obsessive-compulsive and spectrum disorders in children and adolescents.,, 2006, 29,, 353-370,[http:\/\/dx.doi.org\/10.1016\/j.psc.2006.02.012]. [PMID: 16650713].","journal-title":"Psychiatr Clin North Am"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/0954026021000046146","volume":"15","author":"Heyman I.","year":"2003","unstructured":"Heyman I, Fombonne E, Simmons H, Ford T, Meltzer H, Goodman R. Int Rev Psychiatry, Prevalence of obsessive-compulsive disorder in the British nationwide survey of child mental health.,, 2003, 15,, 178-184,[http:\/\/dx.doi.org\/10.1080\/0954026021 000046146]. [PMID: 12745330].","journal-title":"Int Rev Psychiatry"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1017\/S0033291713000470","volume":"44","author":"Anholt G.E.","year":"2014","unstructured":"Anholt GE, Aderka IM, van Balkom AJ, Smit JH, Schruers K, van der Wee NJ, Eikelenboom M, De Luca V, van Oppen P. Psychol Med, Age of onset in obsessive-compulsive disorder: admixture analysis with a large sample.,, 2014, 44,, 185-194,[http:\/\/ dx.doi.org\/10.1017\/S0033291713000470]. [PMID: 23517651].","journal-title":"Psychol Med"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000064812","volume":"71","author":"Mataix-Cols D.","year":"2002","unstructured":"Mataix-Cols D, Marks IM, Greist JH, Kobak KA, Baer L. Psychother Psychosom, Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behaviour therapy: results from a controlled trial.,, 2002, 71,, 255-262,[http:\/\/ dx.doi.org\/10.1159\/000064812]. [PMID: 12207105].","journal-title":"Psychother Psychosom"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2004.00302.x","volume":"110","author":"Stewart S.E.","year":"2004","unstructured":"Stewart SE, Geller DA, Jenike M, Pauls D, Shaw D, Mullin B, Faraone SV. Acta Psychiatr Scand, Long-term outcome of pediatric obsessive-compulsive disorder: a meta-analysis and qualitative review of the literature.,, 2004, 110,, 4-13,[http:\/\/dx. doi.org\/10.1111\/j.1600-0447.2004.00302.x]. [PMID: 15180774].","journal-title":"Acta Psychiatr Scand"},{"key":"ref=11","year":"2008","unstructured":". The Global Burden of Disease: 2004 Update, ,World Health Organization (WHO), 2008, 110,, 4-,","journal-title":"The Global Burden of Disease: 2004 Update"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.2200","volume":"317","author":"Hirschtritt M.E.","year":"2017","unstructured":"Hirschtritt ME, Bloch MH, Mathews CA. JAMA, Obsessive-compulsive disorder: Advances in diagnosis and treatment.,, 2017, 317,, 1358-1367,[http:\/\/dx.doi.org\/10.1001\/jama.2017.2200]. [PMID: 28384832].","journal-title":"JAMA"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archfami.4.10.857","volume":"4","author":"Leon A.C.","year":"1995","unstructured":"Leon AC, Olfson M, Broadhead WE, Barrett JE, Blacklow RS, Keller MB, Higgins ES, Weissman MM. Arch Fam Med, Prevalence of mental disorders in primary care. Implications for screening.,, 1995, 4,, 857-861,[http:\/\/dx.doi.org\/10.1001\/ archfami.4.10.857]. [PMID: 7551133].","journal-title":"Arch Fam Med"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/13651501.2011.617454","volume":"16","author":"Veldhuis J.","year":"2012","unstructured":"Veldhuis J, Dieleman JP, Wohlfarth T, Storosum JG, van Den Brink W, Sturkenboom MC, Denys D. Int J Psychiatry Clin Pract, Incidence and prevalence of \u201cdiagnosed OCD\u201d in a primary care, treatment seeking, population.,, 2012, 16,, 85-92,[http:\/\/ dx.doi.org\/10.3109\/13651501.2011.617454]. [PMID: 22122660].","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref=15","first-page":"201","volume":"25","author":"Glazier K.","year":"2013","unstructured":"Glazier K, Calixte RM, Rothschild R, Pinto A. Ann Clin Psychiatry, High rates of OCD symptom misidentification by mental health professionals.,, 2013, 25,, 201-209,[PMID: 23926575].","journal-title":"Ann Clin Psychiatry"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/eip.12016","volume":"7","author":"Dell\u2019Osso B.","year":"2013","unstructured":"Dell\u2019Osso B, Camuri G, Benatti B, Buoli M, Altamura AC. Early Interv Psychiatry, Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder.,, 2013, 7,, 374-380,[http:\/\/dx.doi.org\/10.1111\/eip.12016]. [PMID: 23347385].","journal-title":"Early Interv Psychiatry"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/YIC.0b013e3283384c74","volume":"25","author":"Altamura A.C.","year":"2010","unstructured":"Altamura AC, Buoli M, Albano A, Dell\u2019Osso B. Int Clin Psychopharmacol, Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study.,, 2010, 25,, 172-179,[http:\/\/dx.doi.org\/10. 1097\/YIC.0b013e3283384c74]. [PMID: 20305566].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1176\/ps.2007.58.7.977","volume":"58","author":"Torres A.R.","year":"2007","unstructured":"Torres AR, Prince MJ, Bebbington PE, Bhugra DK, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N. Psychiatr Serv, Treatment seeking by individuals with obsessive-compulsive disorder from the british psychiatric morbidity survey of 2000.,, 2007, 58,, 977-982,[http:\/\/dx.doi.org\/ 10.1176\/ps.2007.58.7.977]. [PMID: 17602015].","journal-title":"Psychiatr Serv"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1176\/ajp.2006.163.11.1978","volume":"163","author":"Torres A.R.","year":"2006","unstructured":"Torres AR, Prince MJ, Bebbington PE, Bhugra D, Brugha TS, Farrell M, Jenkins R, Lewis G, Meltzer H, Singleton N. Am J Psychiatry, Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000.,, 2006, 163,, 1978-1985,[http:\/\/dx. doi.org\/10.1176\/ajp.2006.163.11.1978]. [PMID: 17074950].","journal-title":"Am J Psychiatry"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","volume":"3","author":"Skapinakis P.","year":"2016","unstructured":"Skapinakis P, Caldwell DM, Hollingworth W, Bryden P, Fineberg NA, Salkovskis P, Welton NJ, Baxter H, Kessler D, Churchill R, Lewis G. Lancet Psychiatry, Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis.,, 2016, 3,, 730-739,[http:\/\/dx.doi.org\/10.1016\/S2215-0366(16)30069-4]. [PMID: 27318812].","journal-title":"Lancet Psychiatry"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/16506070510043750","volume":"34","author":"Cottraux J.","year":"2005","unstructured":"Cottraux J, Bouvard MA, Milliery M. Cogn Behav Ther, Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder.,, 2005, 34,, 185-192,[http:\/\/dx.doi.org\/10.1080\/16506070510043750]. [PMID: 16201063].","journal-title":"Cogn Behav Ther"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.pnpbp.2005.11.028","volume":"30","author":"Pallanti S.","year":"2006","unstructured":"Pallanti S, Quercioli L. Prog Neuropsychopharmacol Biol Psychiatry, Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines.,, 2006, 30,, 400-412,[http:\/\/dx.doi.org\/10.1016\/j.pnpbp.2005. 11.028]. [PMID: 16503369].","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1176\/appi.ps.54.8.1111","volume":"54","author":"Kaplan A.","year":"2003","unstructured":"Kaplan A, Hollander E. Psychiatr Serv, A review of pharmacologic treatments for obsessive-compulsive disorder.,, 2003, 54,, 1111-1118,[http:\/\/dx.doi.org\/10.1176\/appi.ps.54.8.1111]. [PMID: 12883138].","journal-title":"Psychiatr Serv"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/da.20003","volume":"19","author":"Simpson H.B.","year":"2004","unstructured":"Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, Petkova E, Kjernisted K, Huppert JD, Franklin ME, Davies SO, Campeas R. Depress Anxiety, Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder.,, 2004, 19,, 225-233,[http:\/\/dx.doi.org\/10. 1002\/da.20003]. [PMID: 15274171].","journal-title":"Depress Anxiety"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/030079907X178838","volume":"23","author":"Stein D.J.","year":"2007","unstructured":"Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Curr Med Res Opin, Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.,, 2007, 23,, 701-711,[http:\/\/dx.doi.org\/10.1185\/ 030079907X178838]. [PMID: 17407626].","journal-title":"Curr Med Res Opin"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4088\/JCP.v67n0411","volume":"67","author":"Dell\u2019Osso B.","year":"2006","unstructured":"Dell\u2019Osso B, Nestadt G, Allen A, Hollander E. J Clin Psychiatry, Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.,, 2006, 67,, 600-610,[http:\/\/dx.doi.org\/10.4088\/JCP.v67n0411]. [PMID: 16669725].","journal-title":"J Clin Psychiatry"},{"key":"ref=27","author":"Soomro G.M.","year":"2008","unstructured":"Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Cochrane Database Syst Rev, Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).,, 2008, 67,, 600-,[PMID: 18253995].","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.4088\/JCP.14r09758","volume":"77","author":"Issari Y.","year":"2016","unstructured":"Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. J Clin Psychiatry, Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.,, 2016, 77,, e605-e611,[http:\/\/dx.doi.org\/10.4088\/JCP. 14r09758]. [PMID: 27249090].","journal-title":"J Clin Psychiatry"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/YIC.0b013e32825ea312","volume":"22","author":"Fineberg N.A.","year":"2007","unstructured":"Fineberg NA, Pampaloni I, Pallanti S, Ipser J, Stein DJ. Int Clin Psychopharmacol, Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder.,, 2007, 22,, 313-322,[http:\/\/dx.doi.org\/10.1097\/YIC.0b013e32825 ea312]. [PMID: 17917549].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.euroneuro.2006.11.005","volume":"17","author":"Fineberg N.A.","year":"2007","unstructured":"Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Eur Neuropsychopharmacol, Escitalopram prevents relapse of obsessive-compulsive disorder.,, 2007, 17,, 430-439,[http:\/\/dx.doi.org\/ 10.1016\/j.euroneuro.2006.11.005]. [PMID: 17240120].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jad.2009.06.010","volume":"121","author":"Landeros-Weisenberger A.","year":"2010","unstructured":"Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. J Affect Disord, Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.,, 2010, 121,, 175-179,[http:\/\/dx.doi.org\/10. 1016\/j.jad.2009.06.010]. [PMID: 19577308].","journal-title":"J Affect Disord"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1176\/appi.ajp.160.3.522","volume":"160","author":"Saxena S.","year":"2003","unstructured":"Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR. Am J Psychiatry, Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression.,, 2003, 160,, 522-532,[http:\/\/dx.doi. org\/10.1176\/appi.ajp.160.3.522]. [PMID: 12611834].","journal-title":"Am J Psychiatry"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.156.9.1409","volume":"156","author":"Mataix-Cols D.","year":"1999","unstructured":"Mataix-Cols D, Rauch SL, Manzo PA, Jenike MA, Baer L. Am J Psychiatry, Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.,, 1999, 156,, 1409-1416,[PMID: 10484953].","journal-title":"Am J Psychiatry"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/00004714-200110000-00006","volume":"21","author":"Erzegovesi S.","year":"2001","unstructured":"Erzegovesi S, Cavallini MC, Cavedini P, Diaferia G, Locatelli M, Bellodi L. J Clin Psychopharmacol, Clinical predictors of drug response in obsessive-compulsive disorder.,, 2001, 21,, 488-492,[http:\/\/dx.doi.org\/10.1097\/00004714-200110000-00006]. [PMID: 11593074].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1440-1819.2005.01451.x-i1","volume":"60","author":"T\u00fckel R.","year":"2006","unstructured":"T\u00fckel R, Bozkurt O, Polat A, Gen\u00e7 A, Atli H. Psychiatry Clin Neurosci, Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder.,, 2006, 60,, 404-409,[PMID: 16884439].","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4088\/JCP.v64n0919","volume":"64","author":"Hollander E.","year":"2003","unstructured":"Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB. J Clin Psychiatry, Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine.,, 2003, 64,, 1113-1121,[http:\/\/dx.doi.org\/10.4088\/ JCP.v64n0919]. [PMID: 14628989].","journal-title":"J Clin Psychiatry"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.280.8.708","volume":"280","author":"Stein M.B.","year":"1998","unstructured":"Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. JAMA, Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.,, 1998, 280,, 708-713,[http:\/\/dx.doi.org\/10.1001\/jama.280.8.708]. [PMID: 9728642].","journal-title":"JAMA"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/NDT.S17032","volume":"7","author":"Goljevscek S.","year":"2011","unstructured":"Goljevscek S, Carvalho LA. Neuropsychiatr Dis Treat, Current management of obsessive and phobic states.,, 2011, 7,, 599-610,[http:\/\/dx.doi.org\/10.2147\/NDT.S17032]. [PMID: 22003299].","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1192\/bjp.169.4.468","volume":"169","author":"Zohar J.","year":"1996","unstructured":"Zohar J, Judge R. Br J Psychiatry, Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder.,, 1996, 169,, 468-474,[http:\/\/dx.doi.org\/10.1192\/bjp.169.4.468]. [PMID: 8894198].","journal-title":"Br J Psychiatry"},{"key":"ref=40","first-page":"215","volume":"31","author":"Li J.","year":"1998","unstructured":"Li J, Xiang H, Du H. Chin J Psychiatry, Clinical controlled study of paroxetine and clomipramine in treatment of obsessive- compulsive disorder.,, 1998, 31,, 215-217,","journal-title":"Chin J Psychiatry"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.chi.0000138356.29099.f1","volume":"43","author":"Geller D.A.","year":"2004","unstructured":"Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, Perera P, Machin A, Gardiner C. J Am Acad Child Adolesc Psychiatry, Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.,, 2004, 43,, 1387-1396,[http:\/\/dx.doi.org\/10.1097\/01.chi.0000138356. 29099.f1]. [PMID: 15502598].","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1440-1819.2004.01278.x","volume":"58","author":"Kamijima K.","year":"2004","unstructured":"Kamijima K, Murasaki M, Asai M, Higuchi T, Nakajima T, Taga C, Matsunaga H. Psychiatry Clin Neurosci, Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients.,, 2004, 58,, 427-433,[http:\/\/dx.doi.org\/10.1111\/j.1440-1819.2004.01278.x]. [PMID: 15298657].","journal-title":"Psychiatry Clin Neurosci"},{"key":"ref=43","first-page":"603","volume":"19","author":"Ushijima S.","year":"1997","unstructured":"Ushijima S, Kamijima K, Asai M, Murasaki M, Nakajima T, Kudo Y, Tashiro N, Kurihara M, Miura S. Jpn J Neuropsychoph, Clinical evaluation of sertraline hydrochloride, a selective serotonin reuptake inhibitor in the treatment of obsessive- compulsive disorder: A double blind placebo controlled trial.,, 1997, 19,, 603-623,","journal-title":"Jpn J Neuropsychoph"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/10401239209150443","volume":"4","author":"Mallya G.K.","year":"1992","unstructured":"Mallya GK, White K, Waternaux C, Quay S. Ann Clin Psychiatry, Short- and long-term treatment with obsessive-compulsive disorder with fluvoxamine.,, 1992, 4,, 77-80,[http:\/\/dx.doi.org\/10. 3109\/10401239209150443].","journal-title":"Ann Clin Psychiatry"},{"key":"ref=45","first-page":"409","volume":"12","author":"Nakajima T.","year":"1996","unstructured":"Nakajima T, Kudo Y, Yamashita I, Asai M, Kamijima K, Murasaki M, Yamaguchi N, Saito M, Yamawaki S, Nishizono M, Hishikawa Y, Machiyama Y, Yamauchi T, Moriya N, Toru M, Hirose T, Kojima T, Shimizu M, Tamura A, Endo S, Suzuki J, Takemasa K, Uno M, Hasegawa K, Kariya T. J Clin Ther Med, Clinical usefulness of Fluvoxamine Maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: A double blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110.,, 1996, 12,, 409-437,[Rinshou Iyaku].","journal-title":"J Clin Ther Med"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1159\/000086317","volume":"74","author":"Nakatani E.","year":"2005","unstructured":"Nakatani E, Nakagawa A, Nakao T, Yoshizato C, Nabeyama M, Kudo A, Isomura K, Kato N, Yoshioka K, Kawamoto M. Psychother Psychosom, A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine.,, 2005, 74,, 269-276,[http:\/\/dx. doi.org\/10.1159\/000086317]. [PMID: 16088264].","journal-title":"Psychother Psychosom"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4088\/JCP.v64n0604","volume":"64","author":"Hollander E.","year":"2003","unstructured":"Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM. J Clin Psychiatry, A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.,, 2003, 64,, 640-647,[http:\/\/dx.doi.org\/10.4088\/ JCP.v64n0604]. [PMID: 12823077].","journal-title":"J Clin Psychiatry"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00004850-199603000-00003","volume":"11","author":"Goodman W.K.","year":"1996","unstructured":"Goodman WK, Kozak MJ, Liebowitz M, White KL. Int Clin Psychopharmacol, Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial.,, 1996, 11,, 21-29,[http:\/\/dx.doi.org\/10.1097\/ 00004850-199603000-00003]. [PMID: 8732310].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","volume":"40","author":"Riddle M.A.","year":"2001","unstructured":"Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, Greist JH, Holland D, McConville BJ, Pigott T, Walkup JT. J Am Acad Child Adolesc Psychiatry, Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.,, 2001, 40,, 222-229,[http:\/\/dx.doi.org\/10.1097\/00004583-200102000-00017]. [PMID: 11211371].","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-0447.2006.00767.x","volume":"113","author":"O\u2019Connor K.P.","year":"2006","unstructured":"O\u2019Connor KP, Aardema F, Robillard S, Guay S, P\u00e9lissier MC, Todorov C, Borgeat F, Leblanc V, Grenier S, Doucet P. Acta Psychiatr Scand, Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder.,, 2006, 113,, 408-419,[http:\/\/dx.doi.org\/10.1111\/j.1600-0447.2006.00767. x]. [PMID: 16603032].","journal-title":"Acta Psychiatr Scand"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","volume":"46","author":"Goodman W.K.","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Arch Gen Psychiatry, Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo.,, 1989, 46,, 36-44,[http:\/\/dx.doi. org\/10.1001\/archpsyc.1989.01810010038006]. [PMID: 2491940].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/ajp.147.10.1393","volume":"147","author":"Jenike M.A.","year":"1990","unstructured":"Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J. Am J Psychiatry, A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory.,, 1990, 147,, 1209-1215,[http:\/\/dx.doi.org\/10.1176\/ajp.147.9.1209]. [PMID: 2143637].","journal-title":"Am J Psychiatry"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1176\/ajp.156.5.756","volume":"156","author":"Stein M.B.","year":"1999","unstructured":"Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Am J Psychiatry, Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study.,, 1999, 156,, 756-760,[PMID: 10327910].","journal-title":"Am J Psychiatry"},{"key":"ref=54","first-page":"167","volume":"32","author":"Ravizza L.","year":"1996","unstructured":"Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Psychopharmacol Bull, Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).,, 1996, 32,, 167-173,[PMID: 8927668].","journal-title":"Psychopharmacol Bull"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1590\/S1516-44462007000400003","volume":"29","author":"Stein D.J.","year":"2007","unstructured":"Stein DJ, Andersen EW, Overo KF. Rev Bras Psiquiatr, Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.,, 2007, 29,, 303-307,[http:\/\/dx.doi.org\/10.1590\/S1516-44462007000400003]. [PMID: 18200396].","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","volume":"16","author":"Montgomery S.A.","year":"2001","unstructured":"Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. Int Clin Psychopharmacol, Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.,, 2001, 16,, 75-86,[http:\/\/dx.doi.org\/10.1097\/00004850-200103000-00002]. [PMID: 11236072].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/hup.436","volume":"17","author":"Atmaca M.","year":"2002","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Unal A. Hum Psychopharmacol, Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings.,, 2002, 17,, 401-405,[http:\/\/dx.doi.org\/10.1002\/hup.436]. [PMID: 12457375].","journal-title":"Hum Psychopharmacol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1017\/S1092852900014024","volume":"13","author":"Marazziti D.","year":"2008","unstructured":"Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M, Mungai F, Catena Dell\u2019osso M. CNS Spectr, Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients.,, 2008, 13,, 971-976,[http:\/\/ dx.doi.org\/10.1017\/S1092852900014024]. [PMID: 19037176].","journal-title":"CNS Spectr"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00213-002-1364-z","volume":"167","author":"S\u00e1nchez C.","year":"2003","unstructured":"S\u00e1nchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O. Psychopharmacology (Berl), Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.,, 2003, 167,, 353-362,[http:\/\/dx.doi.org\/10.1007\/s00213-002-1364-z]. [PMID: 12719960].","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=60","first-page":"1102","volume":"29","author":"von Moltke L.L.","year":"2001","unstructured":"von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Drug Metab Dispos, Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.,, 2001, 29,, 1102-1109,[PMID: 11454728].","journal-title":"Drug Metab Dispos"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4088\/PCC.v04n0107","volume":"4","author":"Burke W.J.","year":"2002","unstructured":"Burke WJ, Kratochvil CJ. Prim Care Companion J Clin Psychiatry, Stereoisomers in Psychiatry: The Case of Escitalopram.,, 2002, 4,, 20-24,[http:\/\/dx.doi.org\/10.4088\/PCC.v04n0107]. [PMID: 15014731].","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/da.20014","volume":"19","author":"Lader M.","year":"2004","unstructured":"Lader M, Stender K, B\u00fcrger V, Nil R. Depress Anxiety, Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study.,, 2004, 19,, 241-248,[http:\/\/dx.doi. org\/10.1002\/da.20014]. [PMID: 15274173].","journal-title":"Depress Anxiety"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","volume":"51","author":"Tollefson G.D.","year":"1994","unstructured":"Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ. Arch Gen Psychiatry, kominguez, R.A.; Koran, L.M.; Shear, M.K.; Goodman, W.; Genduso, L.A. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.,, 1994, 51,, 559-567,[http:\/\/dx.doi.org\/10.1001\/ archpsyc.1994.03950070051010]. [PMID: 8031229].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/00004714-200102000-00009","volume":"21","author":"Romano S.","year":"2001","unstructured":"Romano S, Goodman W, Tamura R, Gonzales J. J Clin Psychopharmacol, Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo.,, 2001, 21,, 46-52,[http:\/\/dx.doi.org\/10.1097\/00004714-200102000-00009]. [PMID: 11199947].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/appi.psy.45.5.438","volume":"45","author":"Phillips K.A.","year":"2004","unstructured":"Phillips KA, Rasmussen SA. Psychosomatics, Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study.,, 2004, 45,, 438-444,[http:\/\/dx.doi.org\/10.1176\/appi.psy.45.5.438]. [PMID: 15345790].","journal-title":"Psychosomatics"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archpsyc.61.10.1005","volume":"61","author":"Davidson J.R.","year":"2004","unstructured":"Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, Zhao N, Connor KM, Lynch TR, Gadde KM. Arch Gen Psychiatry, Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.,, 2004, 61,, 1005-1013,[http:\/\/dx.doi.org\/10.1001\/archpsyc.61.10.1005]. [PMID: 15466674].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/00004583-199211000-00011","volume":"31","author":"Riddle M.A.","year":"1992","unstructured":"Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, Smith JC, Leckman JF, Cohen DJ. J Am Acad Child Adolesc Psychiatry, Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.,, 1992, 31,, 1062-1069,[http:\/\/dx.doi.org\/10. 1097\/00004583-199211000-00011]. [PMID: 1429406].","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","volume":"3","author":"Montgomery S.A.","year":"1993","unstructured":"Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, Birkett M, Wood AJ. Eur Neuropsychopharmacol, A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder.,, 1993, 3,, 143-152,[http:\/\/dx.doi.org\/10.1016\/0924-977X(93)90266-O]. [PMID: 8364350].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-200107000-00011","volume":"40","author":"Geller D.A.","year":"2001","unstructured":"Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG. J Am Acad Child Adolesc Psychiatry, Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.,, 2001, 40,, 773-779,[http:\/\/dx.doi.org\/10.1097\/00004583-200107000-00011]. [PMID: 11437015].","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=70","first-page":"69","volume":"55","author":"Tollefson G.D.","year":"1994","unstructured":"Tollefson GD, Birkett M, Koran L, Genduso L. J Clin Psychiatry, Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.,, 1994, 55,, 69-76,[PMID: 7961535].","journal-title":"J Clin Psychiatry"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1176\/ajp.154.9.1261","volume":"154","author":"Jenike M.A.","year":"1997","unstructured":"Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Am J Psychiatry, Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder.,, 1997, 154,, 1261-1264,[http:\/\/dx.doi.org\/10.1176\/ajp.154.9.1261]. [PMID: 9286186].","journal-title":"Am J Psychiatry"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","volume":"52","author":"Greist J.","year":"1995","unstructured":"Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C. Arch Gen Psychiatry, Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder.,, 1995, 52,, 289-295,[http:\/\/dx.doi. org\/10.1001\/archpsyc.1995.03950160039008]. [PMID: 7702445].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4088\/JCP.v64n0708","volume":"64","author":"Liebowitz M.R.","year":"2003","unstructured":"Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, Fayyad R, Clary CM. J Clin Psychiatry, Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study.,, 2003, 64,, 785-792,[http:\/\/dx.doi.org\/10.4088\/JCP.v64n0708]. [PMID: 12934979].","journal-title":"J Clin Psychiatry"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1176\/appi.ajp.158.2.275","volume":"158","author":"Van Ameringen M.A.","year":"2001","unstructured":"Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP. Am J Psychiatry, Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study.,, 2001, 158,, 275-281,[http:\/\/dx.doi.org\/10.1176\/appi.ajp.158.2.275]. [PMID: 11156811].","journal-title":"Am J Psychiatry"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00004714-199904000-00013","volume":"19","author":"Kronig M.H.","year":"1999","unstructured":"Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillips K, Du Pont IJ. J Clin Psychopharmacol, Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder.,, 1999, 19,, 172-176,[http:\/\/dx.doi.org\/10.1097\/00004714-199904000-00013]. [PMID: 10211919].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1176\/appi.ajp.159.1.88","volume":"159","author":"Koran L.M.","year":"2002","unstructured":"Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D. Am J Psychiatry, Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder.,, 2002, 159,, 88-95,[http:\/\/dx.doi.org\/10.1176\/appi.ajp.159.1.88]. [PMID: 11772695].","journal-title":"Am J Psychiatry"},{"key":"ref=77","first-page":"279","volume":"26","author":"Chouinard G.","year":"1990","unstructured":"Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA. Psychopharmacol Bull, Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.,, 1990, 26,, 279-284,[PMID: 2274626].","journal-title":"Psychopharmacol Bull"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v67n0103","volume":"67","author":"Ninan P.T.","year":"2006","unstructured":"Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, Robinson DG, Crits-Christoph P, Mandel FS, Austin C. J Clin Psychiatry, High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.,, 2006, 67,, 15-22,[http:\/\/ dx.doi.org\/10.4088\/JCP.v67n0103]. [PMID: 16426083].","journal-title":"J Clin Psychiatry"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1037\/0022-006X.65.1.44","volume":"65","author":"Abramowitz J.S.","year":"1997","unstructured":"Abramowitz JS. J Consult Clin Psychol, Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review.,, 1997, 65,, 44-52,[http:\/\/dx. doi.org\/10.1037\/0022-006X.65.1.44]. [PMID: 9103733].","journal-title":"J Consult Clin Psychol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","volume":"162","author":"Foa E.B.","year":"2005","unstructured":"Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, Huppert JD, Kjernisted K, Rowan V, Schmidt AB, Simpson HB, Tu X. Am J Psychiatry, Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.,, 2005, 162,, 151-161,[http:\/\/dx.doi.org\/10.1176\/appi. ajp.162.1.151]. [PMID: 15625214].","journal-title":"Am J Psychiatry"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00131746-200005000-00002","volume":"6","author":"Fallon B.A.","year":"2000","unstructured":"Fallon BA, Mathew SJ. J Psychiatr Pract, Biological therapies for obsessive-compulsive disorder.,, 2000, 6,, 113-128,[http:\/\/dx.doi.org\/10.1097\/00131746-200005000-00002]. [PMID: 15990479].","journal-title":"J Psychiatr Pract"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1176\/ajp.146.10.1328","volume":"146","author":"Jenike M.A.","year":"1989","unstructured":"Jenike MA, Baer L, Summergrad P, Weilburg JB, Holland A, Seymour R. Am J Psychiatry, Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients.,, 1989, 146,, 1328-1330,[http:\/\/dx.doi.org\/10.1176\/ ajp.146.10.1328]. [PMID: 2675643].","journal-title":"Am J Psychiatry"},{"key":"ref=83","first-page":"292","volume":"51","author":"Greist J.H.","year":"1990","unstructured":"Greist JH, Jefferson JW, Rosenfeld R, Gutzmann LD, March JS, Barklage NE. J Clin Psychiatry, Clomipramine and obsessive compulsive disorder: a placebo-controlled double-blind study of 32 patients.,, 1990, 51,, 292-297,[PMID: 2195006].","journal-title":"J Clin Psychiatry"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","volume":"48","year":"1991","unstructured":". Arch Gen Psychiatry, Clomipramine in the treatment of patients with obsessive-compulsive disorder.,, 1991, 48,, 730-738,[http:\/\/dx.doi.org\/10.1001\/archpsyc.1991.01810320054008]. [PMID: 1883256].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=85","first-page":"272","volume":"54","author":"Hoehn-Saric R.","year":"1993","unstructured":"Hoehn-Saric R, McLeod DR, Zimmerli WD, Hipsley PA. J Clin Psychiatry, Symptoms and physiologic manifestations in obsessive compulsive patients before and after treatment with clomipramine.,, 1993, 54,, 272-276,[PMID: 8335655].","journal-title":"J Clin Psychiatry"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00004714-199008000-00005","volume":"10","author":"Mavissakalian M.R.","year":"1990","unstructured":"Mavissakalian MR, Jones B, Olson S, Perel JM. J Clin Psychopharmacol, Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.,, 1990, 10,, 261-268,[http:\/\/dx.doi.org\/10.1097\/00004714-199008000-00005]. [PMID: 2286699].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4088\/JCP.v63n1108","volume":"63","author":"Albert U.","year":"2002","unstructured":"Albert U, Aguglia E, Maina G, Bogetto F. J Clin Psychiatry, Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study.,, 2002, 63,, 1004-1009,[http:\/\/dx.doi.org\/10.4088\/JCP. v63n1108]. [PMID: 12444814].","journal-title":"J Clin Psychiatry"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00004714-199602000-00017","volume":"16","author":"Rauch S.L.","year":"1996","unstructured":"Rauch SL, O\u2019Sullivan RL, Jenike MA. J Clin Psychopharmacol, Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases.,, 1996, 16,, 81-84,[http:\/\/dx. doi.org\/10.1097\/00004714-199602000-00017]. [PMID: 8834427].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=89","first-page":"817","volume":"36","author":"Sevincok L.","year":"2002","unstructured":"Sevincok L, Uygur B. Aust N Z J Psychiatry, Venlafaxine open-label treatment of patients with obsessive-compulsive disorder.,, 2002, 36,, 817-,[http:\/\/dx.doi.org\/10.1046\/j.1440-1614.2002. t01-5-01101c.x]. [PMID: 12406128].","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v64n0508","volume":"64","author":"Hollander E.","year":"2003","unstructured":"Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM. J Clin Psychiatry, Venlafaxine in treatment-resistant obsessive-compulsive disorder.,, 2003, 64,, 546-550,[http:\/\/dx.doi.org\/10.4088\/JCP.v64n0508]. [PMID: 12755657].","journal-title":"J Clin Psychiatry"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/archpsyc.62.2.190","volume":"62","author":"Liebowitz M.R.","year":"2005","unstructured":"Liebowitz MR, Gelenberg AJ, Munjack D. Arch Gen Psychiatry, Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.,, 2005, 62,, 190-198,[http:\/\/dx.doi.org\/10. 1001\/archpsyc.62.2.190]. [PMID: 15699296].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","volume":"177","author":"Stein M.B.","year":"2005","unstructured":"Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Psychopharmacology (Berl), Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.,, 2005, 177,, 280-288,[http:\/\/dx.doi.org\/10.1007\/s00213-004-1957-9]. [PMID: 15258718].","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.jcp.0000095342.32154.54","volume":"23","author":"Denys D.","year":"2003","unstructured":"Denys D, van der Wee N, van Megen HJ, Westenberg HG. J Clin Psychopharmacol, A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.,, 2003, 23,, 568-575,[http:\/\/dx.doi.org\/10.1097\/01.jcp.0000095342.32154.54]. [PMID: 14624187].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4088\/PCC.v09n0311c","volume":"9","author":"Lu\u00eds Blay S.","year":"2007","unstructured":"Lu\u00eds Blay S, Black DW. Prim Care Companion J Clin Psychiatry, A case of obsessive-compulsive disorder responding to duloxetine.,, 2007, 9,, 234-235,[http:\/\/dx.doi.org\/10.4088\/PCC. v09n0311c]. [PMID: 17632660].","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0269881107079865","volume":"22","author":"Dell\u2019osso B.","year":"2008","unstructured":"Dell\u2019osso B, Mundo E, Marazziti D, Altamura AC. J Psychopharmacol (Oxford), Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series.,, 2008, 22,, 210-213,[http:\/\/dx.doi.org\/10. 1177\/0269881107079865]. [PMID: 18208931].","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNF.0b013e31817f8cef","volume":"32","author":"Yeh Y.W.","year":"2009","unstructured":"Yeh YW, Chen CH, Kuo SC, Wang SC, Chen CK, Feng HM. Clin Neuropharmacol, High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission.,, 2009, 32,, 174-176,[http:\/\/dx.doi.org\/10. 1097\/WNF.0b013e31817f8cef]. [PMID: 19483491].","journal-title":"Clin Neuropharmacol"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1055\/s-2007-970061","volume":"40","author":"Yoshida K.","year":"2007","unstructured":"Yoshida K, Higuchi H, Ozaki N. Pharmacopsychiatry, Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.,, 2007, 40,, 84-85,[http:\/\/ dx.doi.org\/10.1055\/s-2007-970061]. [PMID: 17447181].","journal-title":"Pharmacopsychiatry"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/039463201302600203","volume":"26","author":"De Berardis D.","year":"2013","unstructured":"De Berardis D, Conti CM, Marini S, Ferri F, Iasevoli F, Valchera A, Fornaro M, Cavuto M, Srinivasan V, Perna G, Carano A, Piersanti M, Martinotti G, Di Giannantonio M. Int J Immunopathol Pharmacol, Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data.,, 2013, 26,, 299-304,[http:\/\/dx.doi.org\/10.1177\/039463201302600203]. [PMID: 23755745].","journal-title":"Int J Immunopathol Pharmacol"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1744-859X-10-5","volume":"10","author":"Fornaro M.","year":"2011","unstructured":"Fornaro M. Ann Gen Psychiatry, Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series.,, 2011, 10,, 5-,[http:\/\/dx.doi.org\/10.1186\/1744-859X-10-5]. [PMID: 21356085].","journal-title":"Ann Gen Psychiatry"},{"key":"ref=100","first-page":"179","volume":"25","author":"Tzavellas E.","year":"2014","unstructured":"Tzavellas E, Karaiskos D, Ilias I, Liappas I, Paparrigopoulos T. Psychiatriki, Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.,, 2014, 25,, 179-184,[PMID: 25367661].","journal-title":"Psychiatriki"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jad.2011.07.022","volume":"135","author":"Roca A.","year":"2011","unstructured":"Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hern\u00e1ndez S, Botet F, Gelabert E, Subir\u00e0 S, Plaza A, Vald\u00e9s M, Martin-Santos R. J Affect Disord, Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose.,, 2011, 135,, 208-215,[http:\/\/dx.doi. org\/10.1016\/j.jad.2011.07.022]. [PMID: 21890210].","journal-title":"J Affect Disord"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4088\/JCP.v66n0415","volume":"66","author":"Koran L.M.","year":"2005","unstructured":"Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. J Clin Psychiatry, Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation.,, 2005, 66,, 515-520,[http:\/\/dx.doi.org\/10.4088\/JCP. v66n0415]. [PMID: 15816795].","journal-title":"J Clin Psychiatry"},{"key":"ref=103","first-page":"156","volume":"12","author":"Pigott T.A.","year":"1992","unstructured":"Pigott TA, L\u2019Heureux F, Rubenstein CS, Bernstein SE, Hill JL, Murphy DL. J Clin Psychopharmacol, A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder.,, 1992, 12,, 156-162,","journal-title":"J Clin Psychopharmacol"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archpsyc.57.8.794","volume":"57","author":"McDougle C.J.","year":"2000","unstructured":"McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. Arch Gen Psychiatry, A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.,, 2000, 57,, 794-801,[http:\/\/dx.doi.org\/10.1001\/archpsyc.57.8.794]. [PMID: 10920469].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881108096508","volume":"24","author":"Ravindran L.N.","year":"2010","unstructured":"Ravindran LN, Jung SM, Ravindran AV. J Psychopharmacol (Oxford), Intravenous anti-obsessive agents: a review.,, 2010, 24,, 287-296,[http:\/\/dx.doi.org\/10.1177\/0269881108096508]. [PMID: 18801828].","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4088\/JCP.v63n0908","volume":"63","author":"Pallanti S.","year":"2002","unstructured":"Pallanti S, Quercioli L, Koran LM. J Clin Psychiatry, Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.,, 2002, 63,, 796-801,[http:\/\/dx.doi.org\/10.4088\/ JCP.v63n0908]. [PMID: 12363120].","journal-title":"J Clin Psychiatry"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archpsyc.55.10.918","volume":"55","author":"Fallon B.A.","year":"1998","unstructured":"Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, Goetz D, Klein DF. Arch Gen Psychiatry, Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study.,, 1998, 55,, 918-924,[http:\/\/dx.doi.org\/10.1001\/archpsyc.55.10. 918]. [PMID: 9783563].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1176\/ajp.154.3.396","volume":"154","author":"Koran L.M.","year":"1997","unstructured":"Koran LM, Sallee FR, Pallanti S. Am J Psychiatry, Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder.,, 1997, 154,, 396-401,[http:\/\/dx.doi.org\/10. 1176\/ajp.154.3.396]. [PMID: 9054789].","journal-title":"Am J Psychiatry"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/YIC.0b013e3282f0f0c5","volume":"23","author":"Rabinowitz I.","year":"2008","unstructured":"Rabinowitz I, Baruch Y, Barak Y. Int Clin Psychopharmacol, High-dose escitalopram for the treatment of obsessive-compulsive disorder.,, 2008, 23,, 49-53,[http:\/\/dx.doi.org\/10.1097\/YIC. 0b013e3282f0f0c5]. [PMID: 18090508].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/YIC.0b013e32833119d8","volume":"24","author":"Dougherty D.D.","year":"2009","unstructured":"Dougherty DD, Jameson M, Deckersbach T, Loh R, Thompson-Hollands J, Jenike M, Keuthen NJ. Int Clin Psychopharmacol, Open-label study of high (30 mg) and moderate (20 mg) dose escitalopram for the treatment of obsessive-compulsive disorder.,, 2009, 24,, 306-311,[http:\/\/dx.doi.org\/10.1097\/YIC. 0b013e32833119d8]. [PMID: 19730388].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=111","first-page":"20","volume":"63","author":"Hollander E.","year":"2002","unstructured":"Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J. J Clin Psychiatry, Refractory obsessive-compulsive disorder: state-of-the-art treatment.,, 2002, 63,, 20-29,[PMID: 12027116].","journal-title":"J Clin Psychiatry"},{"key":"ref=112","first-page":"11","volume":"65","author":"Denys D.","year":"2004","unstructured":"Denys D, Zohar J, Westenberg HG. J Clin Psychiatry, The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.,, 2004, 65,, 11-17,[PMID: 15554783].","journal-title":"J Clin Psychiatry"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphar.2013.00099","volume":"4","author":"Schirmbeck F.","year":"2013","unstructured":"Schirmbeck F, Zink M. Front Pharmacol, Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors.,, 2013, 4,, 99-,[http:\/\/dx.doi.org\/10. 3389\/fphar.2013.00099]. [PMID: 23950745].","journal-title":"Front Pharmacol"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1176\/ajp.107.6.455","volume":"107","author":"Gordon A.","year":"1950","unstructured":"Gordon A. Am J Psychiatry, Transition of obsessions into delusions. Evaluation of obsessional phenomena from the prognostic standpoint.,, 1950, 107,, 455-458,[http:\/\/dx.doi.org\/10.1176\/ ajp.107.6.455]. [PMID: 14838150].","journal-title":"Am J Psychiatry"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000285001","volume":"29","author":"Klemperer F.","year":"1996","unstructured":"Klemperer F. Psychopathology, Compulsions developing into command hallucinations.,, 1996, 29,, 249-251,[http:\/\/dx.doi.org\/ 10.1159\/000285001]. [PMID: 8865357].","journal-title":"Psychopathology"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.comppsych.2014.09.015","volume":"56","author":"Devi S.","year":"2015","unstructured":"Devi S, Rao NP, Badamath S, Chandrashekhar CR, Janardhan Reddy YC. Compr Psychiatry, Prevalence and clinical correlates of obsessive-compulsive disorder in schizophrenia.,, 2015, 56,, 141-148,[http:\/\/dx.doi.org\/10.1016\/j.comppsych.2014.09.015]. [PMID: 25308405].","journal-title":"Compr Psychiatry"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1176\/ajp.153.4.466","volume":"153","author":"Kapur S.","year":"1996","unstructured":"Kapur S, Remington G. Am J Psychiatry, Serotonin-dopamine interaction and its relevance to schizophrenia.,, 1996, 153,, 466-476,[http:\/\/dx.doi.org\/10.1176\/ajp.153.4.466]. [PMID: 8599393].","journal-title":"Am J Psychiatry"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/bjp.106.442.93","volume":"106","author":"Pollitt J.D.","year":"1960","unstructured":"Pollitt JD. J Ment Sci, Natural history studies in mental illness. A discussion based on a pilot study of obsessional states.,, 1960, 106,, 93-113,[http:\/\/dx.doi.org\/10.1192\/bjp.106.442.93]. [PMID: 14433876].","journal-title":"J Ment Sci"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.107.448.382","volume":"107","author":"Ingram I.M.","year":"1961","unstructured":"Ingram IM. J Ment Sci, Obsessional illness in mental hospital patients.,, 1961, 107,, 382-402,[http:\/\/dx.doi.org\/10.1192\/bjp.107. 448.382]. [PMID: 13717718].","journal-title":"J Ment Sci"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1192\/bjp.113.501.823","volume":"113","author":"Lo W.H.","year":"1967","unstructured":"Lo WH. Br J Psychiatry, A follow-up study of obsessional neurotics in Hong Kong Chinese.,, 1967, 113,, 823-832,[http:\/\/dx.doi.org\/10.1192\/bjp.113.501.823]. [PMID: 6048368].","journal-title":"Br J Psychiatry"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0010-440X(76)90035-3","volume":"17","author":"Welner A.","year":"1976","unstructured":"Welner A, Reich T, Robins E, Fishman R, Van Doren T. Compr Psychiatry, Obsessive-compulsive neurosis: record, follow-up, and family studies. I. Inpatient record study.,, 1976, 17,, 527-539,[http:\/\/dx.doi.org\/10.1016\/0010-440X(76)90035-3]. [PMID: 963994].","journal-title":"Compr Psychiatry"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/archpsyc.1986.01800030114016","volume":"43","author":"Jenike M.A.","year":"1986","unstructured":"Jenike MA, Baer L, Minichiello WE, Schwartz CE, Carey RJ. Arch Gen Psychiatry, Coexistent obsessive-compulsive disorder and schizotypal personality disorder: a poor prognostic indicator.,, 1986, 43,, 296-,[http:\/\/dx.doi.org\/10.1001\/archpsyc. 1986.01800030114016]. [PMID: 3954553].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1176\/ajp.145.9.1127","volume":"145","author":"Joffe R.T.","year":"1988","unstructured":"Joffe RT, Swinson RP, Regan JJ. Am J Psychiatry, Personality features of obsessive-compulsive disorder.,, 1988, 145,, 1127-1129,[http:\/\/dx.doi.org\/10.1176\/ajp.145.9.1127]. [PMID: 3414855].","journal-title":"Am J Psychiatry"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archpsyc.1990.01810210034005","volume":"47","author":"Baer L.","year":"1990","unstructured":"Baer L, Jenike MA, Ricciardi JN, Holland AD, Seymour RJ, Minichiello WE, Buttolph ML. Arch Gen Psychiatry, Standardized assessment of personality disorders in obsessive-compulsive disorder.,, 1990, 47,, 826-830,[http:\/\/dx.doi.org\/10.1001\/ archpsyc.1990.01810210034005]. [PMID: 2393341].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1177\/070674370104600809","volume":"46","author":"Ganesan V.","year":"2001","unstructured":"Ganesan V, Kumar TC, Khanna S. Can J Psychiatry, Obsessive--compulsive disorder and psychosis.,, 2001, 46,, 750-754,[http:\/\/dx.doi.org\/10.1177\/070674370104600809]. [PMID: 11692979].","journal-title":"Can J Psychiatry"},{"key":"ref=126","year":"2007","unstructured":". Practice Guidelines for the Treatment of Patients with Obsessive-Compulsive Disorder, ,American Psychiatric Association, 2007, 46,, 750-,","journal-title":"Practice Guidelines for the Treatment of Patients with Obsessive-Compulsive Disorder"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"Bandelow B.","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, M\u00f6ller HJ, Zohar J, Hollander E, Kasper S, M\u00f6ller HJ, Bandelow B, Allgulander C, Ayuso-Gutierrez J, Baldwin DS, Buenvicius R, Cassano G, Fineberg N, Gabriels L, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, L\u00e9pine JP, Liebowitz MR, Lopez-Ibor JJ, Marazziti D, Miguel EC, Oh KS, Preter M, Rupprecht R, Sato M, Starcevic V, Stein DJ, van Ameringen M, Vega J. World J Biol Psychiatry, World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.,, 2008, 9,, 248-312,[http:\/\/dx.doi.org\/10.1080\/15622970802465807]. [PMID: 18949648].","journal-title":"World J Biol Psychiatry"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1177\/0269881113517955","volume":"28","author":"Van Ameringen M.","year":"2014","unstructured":"Van Ameringen M, Simpson W, Patterson B, Dell\u2019Osso B, Fineberg N, Hollander E, Hranov L, Hranov G, Lochner C, Karamustafalioglu O, Marazziti D, Menchon JM, Nicolini H, Pallanti S, Stein DJ, Zohar J. J Psychopharmacol (Oxford), Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers.,, 2014, 28,, 596-602,[http:\/\/dx.doi.org\/10.1177\/0269881113517955]. [PMID: 24429223].","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.162.2.377","volume":"162","author":"Phillips K.A.","year":"2005","unstructured":"Phillips KA. Am J Psychiatry, Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.,, 2005, 162,, 377-379,[http:\/\/dx.doi.org\/10.1176\/appi.ajp.162.2.377]. [PMID: 15677604].","journal-title":"Am J Psychiatry"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/YIC.0000000000000127","volume":"31","author":"Albert U.","year":"2016","unstructured":"Albert U, Carmassi C, Cosci F, De Cori D, Di Nicola M, Ferrari S, Poloni N, Tarricone I, Fiorillo A. Int Clin Psychopharmacol, Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review.,, 2016, 31,, 249-258,[http:\/\/dx.doi.org\/10.1097\/YIC. 0000000000000127]. [PMID: 26974213].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.2174\/0929867325666171222163645","volume":"25","author":"Albert U.","year":"2018","unstructured":"Albert U, Marazziti D, Di Salvo G, Solia F, Rosso G, Maina G. Curr Med Chem, A systematic review of evidence-based treatment strategies for obsessive-compulsive disorder resistant to first-line pharmacotherapy.,, 2018, 25,, 5647-5661,[http:\/\/dx. doi.org\/10.2174\/0929867325666171222163645]. [PMID: 29278206].","journal-title":"Curr Med Chem"},{"key":"ref=132","volume":"12","author":"Komossa K.","year":"2010","unstructured":"Komossa K, Depping AM, Meyer M, Kissling W, Leucht S. Cochrane Database Syst Rev, Second-generation antipsychotics for obsessive compulsive disorder.,, 2010, 12,, 5647-,[PMID: 21154394].","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","volume":"16","author":"Dold M.","year":"2013","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Int J Neuropsychopharmacol, Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials.,, 2013, 16,, 557-574,[http:\/\/dx.doi.org\/10.1017\/S146114571 2000740]. [PMID: 22932229].","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4088\/JCP.v66n0610","volume":"66","author":"Li X.","year":"2005","unstructured":"Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. J Clin Psychiatry, Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.,, 2005, 66,, 736-743,[http:\/\/dx.doi.org\/10.4088\/JCP.v66n0610]. [PMID: 15960567].","journal-title":"J Clin Psychiatry"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S1461145703003730","volume":"6","author":"Hollander E.","year":"2003","unstructured":"Hollander E, Baldini RN, Sood E, Pallanti S. Int J Neuropsychopharmacol, Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.,, 2003, 6,, 397-401,[http:\/\/dx.doi.org\/10.1017\/S14611 45703003730]. [PMID: 14604454].","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000093342","volume":"53","author":"Buchsbaum M.S.","year":"2006","unstructured":"Buchsbaum MS, Hollander E, Pallanti S, Baldini RN, Platholi J, Newmark R, Bloom R, Sood E. Neuropsychobiology, Positron emission tomography imaging of risperidone augmentation in serotonin reuptake inhibitor-refractory patients.,, 2006, 53,, 157-168,[http:\/\/dx.doi.org\/10.1159\/000093342]. [PMID: 16707915].","journal-title":"Neuropsychobiology"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2004.04.004","volume":"15","author":"Erzegovesi S.","year":"2005","unstructured":"Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Eur Neuropsychopharmacol, Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.,, 2005, 15,, 69-74,[http:\/\/dx.doi.org\/10. 1016\/j.euroneuro.2004.04.004]. [PMID: 15572275].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","volume":"70","author":"Simpson H.B.","year":"2013","unstructured":"Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R. JAMA Psychiatry, Cognitive-behavioral therapy vs. risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.,, 2013, 70,, 1190-1199,[http:\/\/dx.doi.org\/10.1001\/jamapsychiatry.2013.1932]. [PMID: 24026523].","journal-title":"JAMA Psychiatry"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00044011-200828070-00005","volume":"28","author":"Savas H.A.","year":"2008","unstructured":"Savas HA, Yumru M, Ozen ME. Clin Drug Investig, Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study.,, 2008, 28,, 439-442,[http:\/\/dx.doi.org\/10.2165\/00044011-200828070-00005]. [PMID: 18544004].","journal-title":"Clin Drug Investig"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.euroneuro.2008.01.001","volume":"18","author":"Maina G.","year":"2008","unstructured":"Maina G, Pessina E, Albert U, Bogetto F. Eur Neuropsychopharmacol, 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.,, 2008, 18,, 364-372,[http:\/\/dx.doi.org\/10.1016\/j.euroneuro.2008. 01.001]. [PMID: 18280710].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hup.1169","volume":"26","author":"Selvi Y.","year":"2011","unstructured":"Selvi Y, Atli A, Aydin A, Besiroglu L, Ozdemir P, Ozdemir O. Hum Psychopharmacol, The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.,, 2011, 26,, 51-57,[http:\/\/dx.doi.org\/10.1002\/hup. 1169]. [PMID: 21308781].","journal-title":"Hum Psychopharmacol"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.4088\/JCP.08m04269","volume":"70","author":"Vulink N.C.","year":"2009","unstructured":"Vulink NC, Denys D, Fluitman SB, Meinardi JC, Westenberg HG. J Clin Psychiatry, Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.,, 2009, 70,, 1001-1008,[http:\/\/dx.doi.org\/10.4088\/JCP.08m04269]. [PMID: 19497245].","journal-title":"J Clin Psychiatry"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004850-200507000-00005","volume":"20","author":"Fineberg N.A.","year":"2005","unstructured":"Fineberg NA, Sivakumaran T, Roberts A, Gale T. Int Clin Psychopharmacol, Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study.,, 2005, 20,, 223-226,[http:\/\/dx.doi.org\/10.1097\/ 00004850-200507000-00005]. [PMID: 15933483].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004850-200205000-00004","volume":"17","author":"Atmaca M.","year":"2002","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Gecici O. Int Clin Psychopharmacol, Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.,, 2002, 17,, 115-119,[http:\/\/dx.doi.org\/10.1097\/ 00004850-200205000-00004]. [PMID: 11981352].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.4088\/JCP.v65n0803","volume":"65","author":"Denys D.","year":"2004","unstructured":"Denys D, de Geus F, van Megen HJ, Westenberg HG. J Clin Psychiatry, A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.,, 2004, 65,, 1040-1048,[http:\/\/dx.doi.org\/10.4088\/JCP.v65n0803]. [PMID: 15323587].","journal-title":"J Clin Psychiatry"},{"key":"ref=146","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-244X-5-5","volume":"5","author":"Carey P.D.","year":"2005","unstructured":"Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. BMC Psychiatry, Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study.[ISRCTN83050762].,, 2005, 5,, 5-, [http:\/\/dx.doi.org\/10.1186\/1471-244X-5-5]. [PMID: 15667657].","journal-title":"BMC Psychiatry"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/JCP.0b013e318185e735","volume":"28","author":"Kordon A.","year":"2008","unstructured":"Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F. J Clin Psychopharmacol, Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.,, 2008, 28,, 550-554,[http:\/\/dx.doi.org\/10.1097\/JCP.0b013e318185e735]. [PMID: 18794652].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=148","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv047","volume":"18","author":"Dold M.","year":"2015","unstructured":"Dold M, Aigner M, Lanzenberger R, Kasper S. Int J Neuropsychopharmacol, Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials.,, 2015, 18,, 550-,[http:\/\/dx.doi.org\/10.1093\/ijnp\/pyv047].","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","volume":"14","author":"Veale D.","year":"2014","unstructured":"Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. BMC Psychiatry, Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.,, 2014, 14,, 317-,[http:\/\/dx.doi. org\/10.1186\/s12888-014-0317-5]. [PMID: 25432131].","journal-title":"BMC Psychiatry"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archpsyc.1994.03950040046006","volume":"51","author":"McDougle C.J.","year":"1994","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Arch Gen Psychiatry, Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics.,, 1994, 51,, 302-308,[http:\/\/dx.doi.org\/10.1001\/archpsyc. 1994.03950040046006]. [PMID: 8161290].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-200201000-00006","volume":"17","author":"Mohr N.","year":"2002","unstructured":"Mohr N, Vythilingum B, Emsley RA, Stein DJ. Int Clin Psychopharmacol, Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.,, 2002, 17,, 37-40,[http:\/\/dx.doi.org\/10.1097\/00004850-200201000-00006]. [PMID: 11800505].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0165-1781(00)00203-1","volume":"96","author":"Bogetto F.","year":"2000","unstructured":"Bogetto F, Bellino S, Vaschetto P, Ziero S. Psychiatry Res, Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.,, 2000, 96,, 91-98,[http:\/\/dx.doi.org\/10.1016\/S0165-1781(00)00203-1]. [PMID: 11063782].","journal-title":"Psychiatry Res"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hup.512","volume":"18","author":"Metin O.","year":"2003","unstructured":"Metin O, Yazici K, Tot S, Yazici AE. Hum Psychopharmacol, Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.,, 2003, 18,, 463-467,[http:\/\/dx. doi.org\/10.1002\/hup.512]. [PMID: 12923825].","journal-title":"Hum Psychopharmacol"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.genhosppsych.2010.07.004","volume":"32","author":"Uguz F.","year":"2010","unstructured":"Uguz F. Gen Hosp Psychiatry, Successful treatment of comorbid obsessive-compulsive disorder with aripiprazole in three patients with bipolar disorder.,, 2010, 32,, 556-558,[http:\/\/dx.doi.org\/10. 1016\/j.genhosppsych.2010.07.004]. [PMID: 20851277].","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.4088\/JCP.v69n1202","volume":"69","author":"Glick I.D.","year":"2008","unstructured":"Glick ID, Poyurovsky M, Ivanova O, Koran LM. J Clin Psychiatry, Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients.,, 2008, 69,, 1856-1859,[http:\/\/dx.doi.org\/10.4088\/JCP.v69n1202]. [PMID: 19026264].","journal-title":"J Clin Psychiatry"},{"key":"ref=156","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/cap.2008.0149","volume":"19","author":"Murphy T.K.","year":"2009","unstructured":"Murphy TK, Mutch PJ, Reid JM, Edge PJ, Storch EA, Bengtson M, Yang M. J Child Adolesc Psychopharmacol, Open label aripiprazole in the treatment of youth with tic disorders.,, 2009, 19,, 441-447,[http:\/\/dx.doi.org\/10.1089\/cap.2008.0149]. [PMID: 19702496].","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4088\/JCP.v66n0107","volume":"66","author":"Connor K.M.","year":"2005","unstructured":"Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. J Clin Psychiatry, The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients.,, 2005, 66,, 49-51,[http:\/\/dx.doi.org\/10.4088\/JCP.v66n0107]. [PMID: 15669888].","journal-title":"J Clin Psychiatry"},{"key":"ref=158","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.pnpbp.2007.07.008","volume":"31","author":"da Rocha F.F.","year":"2007","unstructured":"da Rocha FF, Correa H. Prog Neuropsychopharmacol Biol Psychiatry, Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder.,, 2007, 31,, 1550-1551,[http:\/\/dx.doi.org\/10.1016\/j.pnpbp.2007.07.008]. [PMID: 17692447].","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00213-008-1091-1","volume":"197","author":"Sarkar R.","year":"2008","unstructured":"Sarkar R, Klein J, Kr\u00fcger S. Psychopharmacology (Berl), Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.,, 2008, 197,, 687-688,[http:\/\/dx.doi.org\/ 10.1007\/s00213-008-1091-1]. [PMID: 18264798].","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1744-859X-7-26","volume":"7","author":"Fornaro M.","year":"2008","unstructured":"Fornaro M, Gabrielli F, Mattei C, Vinciguerra V, Fornaro P. Ann Gen Psychiatry, Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report.,, 2008, 7,, 26-,[http:\/\/dx.doi.org\/10.1186\/1744-859X-7-26]. [PMID: 19105842].","journal-title":"Ann Gen Psychiatry"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/da.20303","volume":"25","author":"Storch E.A.","year":"2008","unstructured":"Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. Depress Anxiety, Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder.,, 2008, 25,, 172-174,[http:\/\/dx.doi.org\/10.1002\/ da.20303]. [PMID: 17340610].","journal-title":"Depress Anxiety"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/YIC.0b013e32832e9b91","volume":"24","author":"Pessina E.","year":"2009","unstructured":"Pessina E, Albert U, Bogetto F, Maina G. Int Clin Psychopharmacol, Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study.,, 2009, 24,, 265-269,[http:\/\/ dx.doi.org\/10.1097\/YIC.0b013e32832e9b91]. [PMID: 19629012].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/JCP.0b013e3181fab7b1","volume":"30","author":"Masi G.","year":"2010","unstructured":"Masi G, Pfanner C, Millepiedi S, Berloffa S. J Clin Psychopharmacol, Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.,, 2010, 30,, 688-693,[http:\/\/dx.doi.org\/10.1097\/JCP.0b013e3181fab7b1]. [PMID: 21105283].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2174\/1745017901107010107","volume":"7","author":"Delle Chiaie R.","year":"2011","unstructured":"Delle Chiaie R, Scarciglia P, Pasquini M, Caredda M, Biondi M. Clin Pract Epidemiol Ment Health, Aripiprazole augmentation in patients with resistant obsessive compulsive disorder: a pilot study.,, 2011, 7,, 107-111,[http:\/\/dx.doi.org\/10.2174\/17450179011 07010107]. [PMID: 21686322].","journal-title":"Clin Pract Epidemiol Ment Health"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/13651501.2011.605958","volume":"15","author":"Matsunaga H.","year":"2011","unstructured":"Matsunaga H, Hayashida K, Maebayashi K, Mito H, Kiriike N. Int J Psychiatry Clin Pract, A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.,, 2011, 15,, 263-269,[http:\/\/ dx.doi.org\/10.3109\/13651501.2011.605958]. [PMID: 22121999].","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/JCP.0b013e31820e3db6","volume":"31","author":"Muscatello M.R.","year":"2011","unstructured":"Muscatello MR, Bruno A, Pandolfo G, Mic\u00f2 U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA. J Clin Psychopharmacol, Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.,, 2011, 31,, 174-179,[http:\/\/dx.doi.org\/10.1097\/JCP. 0b013e31820e3db6]. [PMID: 21346614].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/da.21996","volume":"29","author":"Sayyah M.","year":"2012","unstructured":"Sayyah M, Sayyah M, Boostani H, Ghaffari SM, Hoseini A. Depress Anxiety, Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial).,, 2012, 29,, 850-854,[http:\/\/dx.doi.org\/10.1002\/da. 21996]. [PMID: 22933237].","journal-title":"Depress Anxiety"},{"key":"ref=168","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"Leucht S.","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, L\u00e4ssig B, Salanti G, Davis JM. Lancet, Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.,, 2013, 382,, 951-962,[http:\/\/dx.doi.org\/10.1016\/S0140-6736(13)60733-3]. [PMID: 23810019].","journal-title":"Lancet"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"e527","DOI":"10.4088\/JCP.12m08278","volume":"74","author":"Storch E.A.","year":"2013","unstructured":"Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK. J Clin Psychiatry, Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.,, 2013, 74,, e527-e532,[http:\/\/dx.doi.org\/10.4088\/JCP.12m08278]. [PMID: 23842022].","journal-title":"J Clin Psychiatry"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1176\/ajp.152.12.1812","volume":"152","author":"McDougle C.J.","year":"1995","unstructured":"McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH. Am J Psychiatry, Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.,, 1995, 152,, 1812-1814,[http:\/\/dx.doi.org\/10.1176\/ ajp.152.12.1812]. [PMID: 8526253].","journal-title":"Am J Psychiatry"},{"key":"ref=171","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/WNF.0b013e31819cc8e6","volume":"32","author":"Englisch S.","year":"2009","unstructured":"Englisch S, Esslinger C, Inta D, Weinbrenner A, Peus V, Gutschalk A, Schirmbeck F, Zink M. Clin Neuropharmacol, Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole.,, 2009, 32,, 227-229,[http:\/\/dx.doi. org\/10.1097\/WNF.0b013e31819cc8e6]. [PMID: 19644230].","journal-title":"Clin Neuropharmacol"},{"key":"ref=172","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.comppsych.2008.11.005","volume":"50","author":"Sa A.R.","year":"2009","unstructured":"Sa AR, Hounie AG, Sampaio AS, Arrais J, Miguel EC, Elkis H. Compr Psychiatry, Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.,, 2009, 50,, 437-442,[http:\/\/dx.doi.org\/10.1016\/j. comppsych.2008.11.005]. [PMID: 19683614].","journal-title":"Compr Psychiatry"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4088\/JCP.11m07164","volume":"73","author":"Scheltema Beduin A.A.","year":"2012","unstructured":"Scheltema Beduin AA, Swets M, Machielsen M, Korver N. J Clin Psychiatry, Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.,, 2012, 73,, 1395-1402,[http:\/\/dx.doi.org\/10. 4088\/JCP.11m07164]. [PMID: 23218156].","journal-title":"J Clin Psychiatry"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1055\/s-0034-1374611","volume":"47","author":"Gahr M.","year":"2014","unstructured":"Gahr M, Rehbaum K, Connemann BJ. Pharmacopsychiatry, Clozapine-associated development of second-onset obsessive compulsive symptoms in schizophrenia: impact of clozapine serum levels and fluvoxamine add-on.,, 2014, 47,, 118-120,[http:\/\/dx. doi.org\/10.1055\/s-0034-1374611]. [PMID: 24846087].","journal-title":"Pharmacopsychiatry"},{"key":"ref=175","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajp.2015.05.002","volume":"15","author":"Grover S.","year":"2015","unstructured":"Grover S, Hazari N, Chakrabarti S, Avasthi A. Asian J Psychiatr, Relationship of obsessive compulsive symptoms\/disorder with clozapine: A retrospective study from a multispeciality tertiary care centre.,, 2015, 15,, 56-61,[http:\/\/dx.doi.org\/10.1016\/j.ajp.2015. 05.002]. [PMID: 26013671].","journal-title":"Asian J Psychiatr"},{"key":"ref=176","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1503\/jpn.140021","volume":"40","author":"Schirmbeck F.","year":"2015","unstructured":"Schirmbeck F, Mier D, Esslinger C, Rausch F, Englisch S, Eifler S, Meyer-Lindenberg A, Kirsch P, Zink M. J Psychiatry Neurosci, Increased orbitofrontal cortex activation associated with \u201cpro-obsessive\u201d antipsychotic treatment in patients with schizophrenia.,, 2015, 40,, 89-99,[PMID: 25268790].","journal-title":"J Psychiatry Neurosci"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2174\/157015912799362724","volume":"10","author":"Schirmbeck F.","year":"2012","unstructured":"Schirmbeck F, Zink M. Curr Neuropharmacol, Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review.,, 2012, 10,, 88-95,[http:\/\/dx.doi.org\/10.2174\/1570159127 99362724]. [PMID: 22942882].","journal-title":"Curr Neuropharmacol"},{"key":"ref=178","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00004583-199503000-00005","volume":"34","author":"Levkovitch Y.","year":"1995","unstructured":"Levkovitch Y, Kronnenberg Y, Gaoni B. J Am Acad Child Adolesc Psychiatry, Can clozapine trigger OCD?,, 1995, 34,, 263-,[http:\/\/dx.doi.org\/10.1097\/00004583-199503000-00005]. [PMID: 7896662].","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1192\/bjp.164.5.687","volume":"164","author":"Eales M.J.","year":"1994","unstructured":"Eales MJ, Layeni AO. Br J Psychiatry, Exacerbation of obsessive-compulsive symptoms associated with clozapine.,, 1994, 164,, 687-688,[http:\/\/dx.doi.org\/10.1192\/bjp.164.5.687]. [PMID: 7921724].","journal-title":"Br J Psychiatry"},{"key":"ref=180","volume":"2016","author":"Leung J.G.","year":"2016","unstructured":"Leung JG, Palmer BA. Case Rep Psychiatry, Psychosis or Obsessions? Clozapine Associated with Worsening Obsessive-Compulsive Symptoms.,, 2016, 2016,, 687-,[http:\/\/dx.doi.org\/ 10.1155\/2016\/2180748]. [PMID: 27313938].","journal-title":"Case Rep Psychiatry"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000325223","volume":"64","author":"Del Casale A.","year":"2011","unstructured":"Del Casale A, Kotzalidis GD, Rapinesi C, Serata D, Ambrosi E, Simonetti A, Pompili M, Ferracuti S, Tatarelli R, Girardi P. Neuropsychobiology, Functional neuroimaging in obsessive-compulsive disorder.,, 2011, 64,, 61-85,[http:\/\/dx.doi.org\/10. 1159\/000325223]. [PMID: 21701225].","journal-title":"Neuropsychobiology"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3109\/15622975.2015.1102323","volume":"17","author":"Del Casale A.","year":"2016","unstructured":"Del Casale A, Rapinesi C, Kotzalidis GD, De Rossi P, Curto M, Janiri D, Criscuolo S, Alessi MC, Ferri VR, De Giorgi R, Sani G, Ferracuti S, Girardi P, Brugnoli R. World J Biol Psychiatry, Executive functions in obsessive-compulsive disorder: An activation likelihood estimate meta-analysis of fMRI studies.,, 2016, 17,, 378-393,[http:\/\/dx.doi.org\/10.3109\/15622975.2015. 1102323]. [PMID: 26642972].","journal-title":"World J Biol Psychiatry"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1017\/S0033291711000419","volume":"41","author":"Schirmbeck F.","year":"2011","unstructured":"Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M. Psychol Med, Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.,, 2011, 41,, 2361-2373,[http:\/\/dx.doi.org\/10.1017\/ S0033291711000419]. [PMID: 21466748].","journal-title":"Psychol Med"},{"key":"ref=184","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-013-3137-2","volume":"230","author":"Cai J.","year":"2013","unstructured":"Cai J, Zhang W, Yi Z, Lu W, Wu Z, Chen J, Yu S, Fang Y, Zhang C. Psychopharmacology (Berl), Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms.,, 2013, 230,, 49-55,[http:\/\/dx.doi.org\/10.1007\/s00213-013-3137-2]. [PMID: 23660601].","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","volume":"28","author":"Lin S.K.","year":"2006","unstructured":"Lin SK, Su SF, Pan CH. Ther Drug Monit, Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms.,, 2006, 28,, 303-307,[http:\/\/dx.doi.org\/10.1097\/01.ftd.0000211801.66569.80]. [PMID: 16778711].","journal-title":"Ther Drug Monit"},{"key":"ref=186","doi-asserted-by":"crossref","first-page":"e1362","DOI":"10.4088\/JCP.12f08200","volume":"73","author":"Andrade C.","year":"2012","unstructured":"Andrade C. J Clin Psychiatry, Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.,, 2012, 73,, e1362-e1364,[http:\/\/dx.doi.org\/ 10.4088\/JCP.12f08200]. [PMID: 23218164].","journal-title":"J Clin Psychiatry"},{"key":"ref=187","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1744-859X-12-40","volume":"12","author":"Ery\u0131lmaz G.","year":"2013","unstructured":"Ery\u0131lmaz G, H\u0131zl\u0131 Sayar G, Ozten E, G\u00f6gceg\u00f6z G\u00fcl I, Karamustafal\u0131o\u011flu O. Ann Gen Psychiatry, Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia.,, 2013, 12,, 40-,[http:\/\/dx.doi.org\/10.1186\/1744-859X-12-40]. [PMID: 24330737].","journal-title":"Ann Gen Psychiatry"},{"key":"ref=188","first-page":"1274","volume":"149","author":"Cassady S.L.","year":"1992","unstructured":"Cassady SL, Thaker GK. Am J Psychiatry, Addition of fluoxetine to clozapine.,, 1992, 149,, 1274-,[PMID: 1503143].","journal-title":"Am J Psychiatry"},{"key":"ref=189","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1176\/ajp.156.6.973a","volume":"156","author":"Strous R.D.","year":"1999","unstructured":"Strous RD, Patel JK, Zimmet S, Green AI. Am J Psychiatry, Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features.,, 1999, 156,, 973-974,[http:\/\/dx.doi.org\/10.1176\/ajp.156.6.973a]. [PMID: 10360153].","journal-title":"Am J Psychiatry"},{"key":"ref=190","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/070674379604101027","volume":"41","author":"Markowitz J.S.","year":"1996","unstructured":"Markowitz JS, Gill HS, Lavia M, Brewerton TD, DeVane CL. Can J Psychiatry, Fluvoxamine-clozapine dose-dependent interaction.,, 1996, 41,, 670-671,[http:\/\/dx.doi.org\/10.1177\/ 070674379604101027]. [PMID: 8978949].","journal-title":"Can J Psychiatry"},{"key":"ref=191","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1055\/s-2007-985885","volume":"40","author":"Zink M.","year":"2007","unstructured":"Zink M, Englisch S, Knopf U, Kuwilsky A, Dressing H. Pharmacopsychiatry, Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms.,, 2007, 40,, 202-203,[http:\/\/dx.doi.org\/10.1055\/s-2007-985885]. [PMID: 17874353].","journal-title":"Pharmacopsychiatry"},{"key":"ref=192","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1097\/YCT.0b013e3181ec0d64","volume":"27","author":"Rao N.P.","year":"2011","unstructured":"Rao NP, Antony A, Raveendranathan D, Venkatasubramanian G, Behere RV, Varambally SS, Gangadhar BN. J ECT, Successful use of maintenance electroconvulsive therapy in the treatment of clozapine-associated obsessive-compulsive symptoms in schizophrenia: a case report.,, 2011, 27,, e37-e38,[http:\/\/dx. doi.org\/10.1097\/YCT.0b013e3181ec0d64]. [PMID: 20938347].","journal-title":"J ECT"},{"key":"ref=193","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1176\/ajp.155.7.921","volume":"155","author":"Kapur S.","year":"1998","unstructured":"Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. Am J Psychiatry, 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.,, 1998, 155,, 921-928,[http:\/\/dx.doi.org\/10.1176\/ajp.155.7.921]. [PMID: 9659858].","journal-title":"Am J Psychiatry"},{"key":"ref=194","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","volume":"11","author":"Bloch M.H.","year":"2006","unstructured":"Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. Mol Psychiatry, A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.,, 2006, 11,, 622-632,[http:\/\/dx.doi.org\/10. 1038\/sj.mp.4001823]. [PMID: 16585942].","journal-title":"Mol Psychiatry"},{"key":"ref=195","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4088\/JCP.08m04369","volume":"70","author":"Matsunaga H.","year":"2009","unstructured":"Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. J Clin Psychiatry, A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.,, 2009, 70,, 863-868,[http:\/\/dx.doi.org\/10.4088\/JCP.08m04369]. [PMID: 19422759].","journal-title":"J Clin Psychiatry"},{"key":"ref=196","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/JCP.0b013e3182367aee","volume":"31","author":"Diniz J.B.","year":"2011","unstructured":"Diniz JB, Shavitt RG, Fossaluza V, Koran L, Pereira CA, Miguel EC. J Clin Psychopharmacol, A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.,, 2011, 31,, 763-768,[http:\/\/dx.doi.org\/10.1097\/JCP. 0b013e3182367aee]. [PMID: 22020357].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=197","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0924-9338(99)80725-1","volume":"14","author":"Pallanti S.","year":"1999","unstructured":"Pallanti S, Quercioli L, Paiva RS, Koran LM. Eur Psychiatry, Citalopram for treatment-resistant obsessive-compulsive disorder.,, 1999, 14,, 101-106,[http:\/\/dx.doi.org\/10.1016\/S0924-9338(99) 80725-1]. [PMID: 10572334].","journal-title":"Eur Psychiatry"},{"key":"ref=198","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/0140-6736(93)92774-N","volume":"342","author":"Neuvonen P.J.","year":"1993","unstructured":"Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Lancet, Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses.,, 1993, 342,, 1419-,[http:\/\/dx.doi.org\/10.1016\/0140-6736(93)92774-N]. [PMID: 7901695].","journal-title":"Lancet"},{"key":"ref=199","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004714-199906000-00021","volume":"19","author":"Rosebush P.I.","year":"1999","unstructured":"Rosebush PI, Margetts P, Mazurek MF. J Clin Psychopharmacol, Serotonin syndrome as a result of clomipramine monotherapy.,, 1999, 19,, 285-287,[http:\/\/dx.doi.org\/10.1097\/00004714-199906000-00021]. [PMID: 10350043].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=200","first-page":"321","volume":"27","author":"Carey P.D.","year":"2012","unstructured":"Carey PD, Lochner C, Kidd M, Van Ameringen M, Stein DJ, Denys D. Int Clin Psychopharmacol, Quetiapine augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: is response to treatment predictable?,, 2012, 27,, 321-325,[PMID: 22859064].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=201","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","volume":"72","author":"Berlin H.A.","year":"2011","unstructured":"Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, Hollander E. J Clin Psychiatry, Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder.,, 2011, 72,, 716-721,[http:\/\/dx.doi.org\/10.4088\/JCP.09m05266gre]. [PMID: 20816027].","journal-title":"J Clin Psychiatry"},{"key":"ref=202","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1092852912000065","volume":"15","author":"Mowla A.","year":"2010","unstructured":"Mowla A, Khajeian AM, Sahraian A, Chohedri AH, Kashkoli F. CNS Spectr, Topiramate Augmentation in Resistant OCD: A Double-Blind Placebo-Controlled Clinical Trial.,, 2010, 15,, 613-617,[http:\/\/dx.doi.org\/10.1017\/S1092852912000065]. [PMID: 24726048].","journal-title":"CNS Spectr"},{"key":"ref=203","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.jcp.0000220524.44905.9f","volume":"26","author":"Rubio A.","year":"2006","unstructured":"Rubio A, Jim\u00e9nez-Arriero MA, Mart\u00ednez-Gras I, Manzanares J, Palomo T. J Clin Psychopharmacol, The effects of topiramate adjunctive treatment addedto antidepressants in patients with resistant obsessive-compulsive disorder.,, 2006, 26,, 341-344, [PMID: 16702907].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=204","first-page":"976","volume":"19","author":"Afshar H.","year":"2014","unstructured":"Afshar H, Akuchekian S, Mahaky B, Zarean E. J Res Med Sci, Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.,, 2014, 19,, 976-981,[PMID: 25538783].","journal-title":"J Res Med Sci"},{"key":"ref=205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/YIC.0b013e3283466657","volume":"26","author":"Oulis P.","year":"2011","unstructured":"Oulis P, Mourikis I, Konstantakopoulos G. Int Clin Psychopharmacol, Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder.,, 2011, 26,, 221-224,[http:\/\/dx.doi. org\/10.1097\/YIC.0b013e3283466657]. [PMID: 21460732].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=206","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/0269881108098809","volume":"24","author":"Uzun O.","year":"2010","unstructured":"Uzun O. J Psychopharmacol (Oxford), Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: a case report.,, 2010, 24,, 425-427,[http:\/\/dx.doi.org\/ 10.1177\/0269881108098809]. [PMID: 19010977].","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=207","volume":"2013","author":"Arrojo-Romero M.","year":"2013","unstructured":"Arrojo-Romero M, Tajes AM, de Leon J. Case Rep Psychiatry, Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder.,, 2013, 2013,, 425-,[http:\/\/dx.doi.org\/10.1155\/2013\/ 612459]. [PMID: 23936714].","journal-title":"Case Rep Psychiatry"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","volume":"26","author":"Bruno A.","year":"2012","unstructured":"Bruno A, Mic\u00f2 U, Pandolfo G, Mallamace D, Abenavoli E, Di Nardo F, D\u2019Arrigo C, Spina E, Zoccali RA, Muscatello MR. J Psychopharmacol (Oxford), Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.,, 2012, 26,, 1456-1462,[http:\/\/dx.doi.org\/10.1177\/0269881111431751]. [PMID: 22351381].","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=209","first-page":"104","volume":"11","author":"Khalkhali M.","year":"2016","unstructured":"Khalkhali M, Aram S, Zarrabi H, Kafie M, Heidarzadeh A. Iran J Psychiatry, Lamotrigine augmentation versus placebo in serotonin reuptake inhibitors-resistant obsessive-compulsive disorder: a randomized controlled trial.,, 2016, 11,, 104-114,[PMID: 27437007].","journal-title":"Iran J Psychiatry"},{"key":"ref=210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00406-007-0798-z","volume":"258","author":"Onder E.","year":"2008","unstructured":"Onder E, Tural U, G\u00f6kbakan M. Eur Arch Psychiatry Clin Neurosci, Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?,, 2008, 258,, 319-323,[http:\/\/ dx.doi.org\/10.1007\/s00406-007-0798-z]. [PMID: 18297416].","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref=211","first-page":"500","volume":"55","author":"Deltito J.A.","year":"1994","unstructured":"Deltito JA. J Clin Psychiatry, Valproate pretreatment for the difficult-to-treat patient with OCD.,, 1994, 55,, 500-,[PMID: 7989288].","journal-title":"J Clin Psychiatry"},{"key":"ref=212","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4088\/JCP.v59n0207b","volume":"59","author":"Cor\u00e1-Locatelli G.","year":"1998","unstructured":"Cor\u00e1-Locatelli G, Greenberg BD, Martin JD, Murphy DL. J Clin Psychiatry, Valproate monotherapy in an SRI-intolerant OCD patient.,, 1998, 59,, 82-,[http:\/\/dx.doi.org\/10.4088\/JCP.v59n0207b]. [PMID: 9501891].","journal-title":"J Clin Psychiatry"},{"key":"ref=213","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1517\/14728222.11.4.527","volume":"11","author":"Thompson A.J.","year":"2007","unstructured":"Thompson AJ, Lummis SC. Expert Opin Ther Targets, The 5-HT3 receptor as a therapeutic target.,, 2007, 11,, 527-540,[http:\/\/dx.doi.org\/10.1517\/14728222.11.4.527]. [PMID: 17373882].","journal-title":"Expert Opin Ther Targets"},{"key":"ref=214","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.4088\/JCP.14f09292","volume":"75","author":"Andrade C.","year":"2014","unstructured":"Andrade C. J Clin Psychiatry, Nonsteroidal anti-inflammatory drugs and 5-HT serotonin receptor antagonists as innovative antipsychotic augmentation treatments for schizophrenia.,, 2014, 75,, e707-e709,[http:\/\/dx.doi.org\/10.4088\/JCP.14f09292]. [PMID: 25093487].","journal-title":"J Clin Psychiatry"},{"key":"ref=215","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4088\/JCP.v66n0413","volume":"66","author":"Toren P.","year":"2005","unstructured":"Toren P, Weizman A, Ratner S, Cohen D, Laor N. J Clin Psychiatry, Ondansetron treatment in Tourette\u2019s disorder: a 3-week, randomized, double-blind, placebo-controlled study.,, 2005, 66,, 499-503,[http:\/\/dx.doi.org\/10.4088\/JCP.v66n0413]. [PMID: 15816793].","journal-title":"J Clin Psychiatry"},{"key":"ref=216","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1176\/appi.ajp.157.2.287","volume":"157","author":"Sirota P.","year":"2000","unstructured":"Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Am J Psychiatry, Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia.,, 2000, 157,, 287-289,[http:\/\/dx.doi.org\/10.1176\/appi. ajp.157.2.287]. [PMID: 10671405].","journal-title":"Am J Psychiatry"},{"key":"ref=217","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","volume":"168","author":"Johnson B.A.","year":"2011","unstructured":"Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang XQ, Liu L, Penberthy JK, DiClemente CC, Li MD. Am J Psychiatry, Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.,, 2011, 168,, 265-275,[http:\/\/dx.doi.org\/ 10.1176\/appi.ajp.2010.10050755]. [PMID: 21247998].","journal-title":"Am J Psychiatry"},{"key":"ref=218","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hup.2461","volume":"30","author":"Serata D.","year":"2015","unstructured":"Serata D, Kotzalidis GD, Rapinesi C, Janiri D, Di Pietro S, Callovini G, Piacentino D, Gasperoni C, Brugnoli R, Ferri VR, Girardi N, Tatarelli R, Ferracuti S, Angeletti G, Girardi P, Del Casale A. Hum Psychopharmacol, Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature.,, 2015, 30,, 70-84,[http:\/\/dx.doi.org\/10.1002\/ hup.2461]. [PMID: 25676060].","journal-title":"Hum Psychopharmacol"},{"key":"ref=219","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4088\/JCP.v64n0907","volume":"64","author":"Hewlett W.A.","year":"2003","unstructured":"Hewlett WA, Schmid SP, Salomon RM. J Clin Psychiatry, Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder.,, 2003, 64,, 1025-1030,[http:\/\/dx.doi.org\/ 10.4088\/JCP.v64n0907]. [PMID: 14628977].","journal-title":"J Clin Psychiatry"},{"key":"ref=220","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2165\/11530240-000000000-00000","volume":"23","author":"Pallanti S.","year":"2009","unstructured":"Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. CNS Drugs, Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.,, 2009, 23,, 1047-1055,[http:\/\/dx.doi.org\/10.2165\/ 11530240-000000000-00000]. [PMID: 19958042].","journal-title":"CNS Drugs"},{"key":"ref=221","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.euroneuro.2013.12.003","volume":"24","author":"Pallanti S.","year":"2014","unstructured":"Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E. Eur Neuropsychopharmacol, Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.,, 2014, 24,, 375-380,[http:\/\/dx.doi.org\/10.1016\/j.euroneuro.2013.12.003]. [PMID: 24406025].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=222","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hup.1145","volume":"25","author":"Soltani F.","year":"2010","unstructured":"Soltani F, Sayyah M, Feizy F, Malayeri A, Siahpoosh A, Motlagh I. Hum Psychopharmacol, A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.,, 2010, 25,, 509-513,[http:\/\/dx.doi.org\/10. 1002\/hup.1145]. [PMID: 20737524].","journal-title":"Hum Psychopharmacol"},{"key":"ref=223","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","volume":"29","author":"Heidari M.","year":"2014","unstructured":"Heidari M, Zarei M, Hosseini SM, Taghvaei R, Maleki H, Tabrizi M, Fallah J, Akhondzadeh S. Int Clin Psychopharmacol, Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.,, 2014, 29,, 344-350,[http:\/\/dx.doi.org\/10.1097\/YIC.0000000000000043]. [PMID: 24850229].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=224","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.4088\/JCP.14f09704","volume":"76","author":"Andrade C.","year":"2015","unstructured":"Andrade C. J Clin Psychiatry, Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder.,, 2015, 76,, e72-e75,[http:\/\/dx.doi.org\/ 10.4088\/JCP.14f09704]. [PMID: 25650682].","journal-title":"J Clin Psychiatry"},{"key":"ref=225","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1520-6394(1997)6:4<170::AID-DA7>3.0.CO;2-G","volume":"6","author":"Shapira N.A.","year":"1997","unstructured":"Shapira NA, Keck PE, Goldsmith TD, McConville BJ, Eis M, McElroy SL. Depress Anxiety, Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder.,, 1997, 6,, 170-173,[http:\/\/dx.doi.org\/10.1002\/ (SICI)1520-6394(1997)6:4<170:AID-DA7>3.0.CO;2-G]. [PMID: 9559288].","journal-title":"Depress Anxiety"},{"key":"ref=226","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/070674379704200624","volume":"42","author":"Warneke L.","year":"1997","unstructured":"Warneke L. Can J Psychiatry, A possible new treatment approach to obsessive-compulsive disorder.,, 1997, 42,, 667-668,[http:\/\/dx.doi.org\/10.1177\/070674379704200624]. [PMID: 9288436].","journal-title":"Can J Psychiatry"},{"key":"ref=227","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1176\/ajp.156.4.660a","volume":"156","author":"Goldsmith T.B.","year":"1999","unstructured":"Goldsmith TB, Shapira NA, Keck PE. Am J Psychiatry, Jr Rapid remission of OCD with tramadol hydrochloride.,, 1999, 156,, 660-661,[PMID: 10200754].","journal-title":"Am J Psychiatry"},{"key":"ref=228","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/JCP.v66n0312","volume":"66","author":"Koran L.M.","year":"2005","unstructured":"Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. J Clin Psychiatry, Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.,, 2005, 66,, 353-359,[http:\/\/dx.doi.org\/10.4088\/JCP.v66n0312]. [PMID: 15766302].","journal-title":"J Clin Psychiatry"},{"key":"ref=229","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2045125312462233","volume":"3","author":"Liddell M.B.","year":"2013","unstructured":"Liddell MB, Aziz V, Briggs P, Kanakkehewa N, Rawi O. Ther Adv Psychopharmacol, Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder.,, 2013, 3,, 15-19,[http:\/\/dx.doi.org\/10.1177\/2045125312462233]. [PMID: 23983988].","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref=230","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajmg.b.20170","volume":"127B","author":"Urraca N.","year":"2004","unstructured":"Urraca N, Camarena B, G\u00f3mez-Caudillo L, Esmer MC, Nicolini H. Am J Med Genet B Neuropsychiatr Genet, Mu opioid receptor gene as a candidate for the study of obsessive compulsive disorder with and without tics.,, 2004, 127B,, 94-96,[http:\/\/dx. doi.org\/10.1002\/ajmg.b.20170]. [PMID: 15108189].","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=231","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-006-0619-5","volume":"190","author":"Rojas-Corrales M.O.","year":"2007","unstructured":"Rojas-Corrales MO, Gibert-Rahola J, Mico JA. Psychopharmacology (Berl), Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A\/C) receptor-mediated behavior.,, 2007, 190,, 221-231,[http:\/\/dx.doi.org\/10.1007\/s00213-006-0619-5]. [PMID: 17102981].","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=232","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.140.9.1219","volume":"140","author":"Insel T.R.","year":"1983","unstructured":"Insel TR, Pickar D. Am J Psychiatry, Naloxone administration in obsessive-compulsive disorder: report of two cases.,, 1983, 140,, 1219-1220,[http:\/\/dx.doi.org\/10.1176\/ajp.140.9.1219]. [PMID: 6614234].","journal-title":"Am J Psychiatry"},{"key":"ref=233","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/0006-3223(95)00632-X","volume":"40","author":"Keuler D.J.","year":"1996","unstructured":"Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. Biol Psychiatry, Behavioral effects of naloxone infusion in obsessive-compulsive disorder.,, 1996, 40,, 154-156,[http:\/\/ dx.doi.org\/10.1016\/0006-3223(95)00632-X]. [PMID: 8793049].","journal-title":"Biol Psychiatry"},{"key":"ref=234","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","volume":"56","author":"Goff D.C.","year":"1999","unstructured":"Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. Arch Gen Psychiatry, A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.,, 1999, 56,, 21-27,[http:\/\/dx.doi.org\/10.1001\/archpsyc.56.1.21]. [PMID: 9892252].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=235","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1176\/ajp.156.3.467","volume":"156","author":"Tsai G.E.","year":"1999","unstructured":"Tsai GE, Falk WE, Gunther J, Coyle JT. Am J Psychiatry, Improved cognition in Alzheimer\u2019s disease with short-term D-cycloserine treatment.,, 1999, 156,, 467-469,[PMID: 10080566].","journal-title":"Am J Psychiatry"},{"key":"ref=236","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1017\/S1092852900020526","volume":"12","author":"Otto M.W.","year":"2007","unstructured":"Otto MW, Basden SL, Leyro TM, McHugh RK, Hofmann SG. CNS Spectr, Clinical perspectives on the combination of D-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders.,, 2007, 12,, 51-56, 59-61,[http:\/\/dx.doi.org\/10.1017\/ S1092852900020526]. [PMID: 17192764].","journal-title":"CNS Spectr"},{"key":"ref=237","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","volume":"22","author":"Walker D.L.","year":"2002","unstructured":"Walker DL, Ressler KJ, Lu KT, Davis M. J Neurosci, Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.,, 2002, 22,, 2343-2351,[http:\/\/dx.doi.org\/10.1523\/JNEUROSCI.22-06-02343.2002]. [PMID: 11896173].","journal-title":"J Neurosci"},{"key":"ref=238","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","volume":"63","author":"Norberg M.M.","year":"2008","unstructured":"Norberg MM, Krystal JH, Tolin DF. Biol Psychiatry, A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.,, 2008, 63,, 1118-1126,[http:\/\/dx.doi. org\/10.1016\/j.biopsych.2008.01.012]. [PMID: 18313643].","journal-title":"Biol Psychiatry"},{"key":"ref=239","volume":"9","author":"Rodrigues H.","year":"2014","unstructured":"Rodrigues H, Figueira I, Lopes A, Gon\u00e7alves R, Mendlowicz MV, Coutinho ES, Ventura P. PLoS One, Does D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis.,, 2014, 9,, 1118-,[http:\/\/dx.doi.org\/10.1371\/journal. pone.0093519]. [PMID: 24991926].","journal-title":"PLoS One"},{"key":"ref=240","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamapsychiatry.2015.0546","volume":"72","author":"Andersson E.","year":"2015","unstructured":"Andersson E, Hedman E, Enander J, Radu DD, Lj\u00f3tsson B, Cervenka S, Isung J, Svanborg C, Mataix-Cols D, Kaldo V, Andersson G, Lindefors N, R\u00fcck C. JAMA Psychiatry, D-cycloserine vs. placebo as adjunct to cognitive behavioral therapy for obsessive-compulsive disorder and interaction with antidepressants: A randomized clinical trial.,, 2015, 72,, 659-667,[http:\/\/dx.doi.org\/10.1001\/jamapsychiatry.2015.0546]. [PMID: 25970252].","journal-title":"JAMA Psychiatry"},{"key":"ref=241","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.biopsych.2007.04.010","volume":"62","author":"Werner-Seidler A.","year":"2007","unstructured":"Werner-Seidler A, Richardson R. Biol Psychiatry, Effects of D-cycloserine on extinction: consequences of prior exposure to imipramine.,, 2007, 62,, 1195-1197,[DOI:10.1016\/j.biopsych. 2007.04.010]. [PMID: 17555721].","journal-title":"Biol Psychiatry"},{"key":"ref=242","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/jamapsychiatry.2016.3955","volume":"74","author":"Mataix-Cols D.","year":"2017","unstructured":"Mataix-Cols D, Fern\u00e1ndez de la Cruz L, Monzani B, Rosenfield D, Andersson E, P\u00e9rez-Vigil A, Frumento P, de Kleine RA, Difede J, Dunlop BW, Farrell LJ, Geller D, Gerardi M, Guastella AJ, Hofmann SG, Hendriks GJ, Kushner MG, Lee FS, Lenze EJ, Levinson CA, McConnell H, Otto MW, Plag J, Pollack MH, Ressler KJ, Rodebaugh TL, Rothbaum BO, Scheeringa MS, Siewert-Siegmund A, Smits JAJ, Storch EA, Str\u00f6hle A, Tart CD, Tolin DF, van Minnen A, Waters AM, Weems CF, Wilhelm S, Wyka K, Davis M, R\u00fcck C, Altemus M, Anderson P, Cukor J, Finck C, Geffken GR, Golfels F, Goodman WK, Gutner C, Heyman I, Jovanovic T, Lewin AB, McNamara JP, Murphy TK, Norrholm S, Thuras P. JAMA Psychiatry, D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.,, 2017, 74,, 501-510,[http:\/\/dx.doi.org\/10.1001\/ jamapsychiatry.2016.3955]. [PMID: 28122091].","journal-title":"JAMA Psychiatry"},{"key":"ref=243","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.biopsych.2006.12.020","volume":"62","author":"Kushner M.G.","year":"2007","unstructured":"Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB. Biol Psychiatry, D-cycloserine augmented exposure therapy for obsessive-compulsive disorder.,, 2007, 62,, 835-838,[http:\/\/dx.doi.org\/10.1016\/j. biopsych.2006.12.020]. [PMID: 17588545].","journal-title":"Biol Psychiatry"},{"key":"ref=244","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/YIC.0b013e32819f8480","volume":"22","author":"Storch E.A.","year":"2007","unstructured":"Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M, Geffken GR, Goodman WK. Int Clin Psychopharmacol, D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.,, 2007, 22,, 230-237,[http:\/\/ dx.doi.org\/10.1097\/YIC.0b013e32819f8480]. [PMID: 17519647].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=245","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1176\/appi.ajp.2007.07050776","volume":"165","author":"Wilhelm S.","year":"2008","unstructured":"Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, Cannistraro P, Jenike MA, Rauch SL. Am J Psychiatry, Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder.,, 2008, 165,, 335-341,[http:\/\/dx.doi.org\/10.1176\/appi.ajp.2007.07050776]. [PMID: 18245177].","journal-title":"Am J Psychiatry"},{"key":"ref=246","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.biopsych.2010.07.015","volume":"68","author":"Storch E.A.","year":"2010","unstructured":"Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M, Geller DA. Biol Psychiatry, A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.,, 2010, 68,, 1073-1076,[http:\/\/dx.doi.org\/10.1016\/j.biopsych.2010.07.015]. [PMID: 20817153].","journal-title":"Biol Psychiatry"},{"key":"ref=247","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1192\/bjp.bp.113.126284","volume":"204","author":"Mataix-Cols D.","year":"2014","unstructured":"Mataix-Cols D, Turner C, Monzani B, Isomura K, Murphy C, Krebs G, Heyman I. Br J Psychiatry, Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial.,, 2014, 204,, 77-78,[http:\/\/dx.doi.org\/10.1192\/bjp.bp.113. 126284]. [PMID: 24262813].","journal-title":"Br J Psychiatry"},{"key":"ref=248","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.brat.2010.03.007","volume":"48","author":"Chasson G.S.","year":"2010","unstructured":"Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S. Behav Res Ther, Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine.,, 2010, 48,, 675-679,[http:\/\/dx. doi.org\/10.1016\/j.brat.2010.03.007]. [PMID: 20362975].","journal-title":"Behav Res Ther"},{"key":"ref=249","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.psc.2010.04.008","volume":"33","author":"Ganasen K.A.","year":"2010","unstructured":"Ganasen KA, Ipser JC, Stein DJ. Psychiatr Clin North Am, Augmentation of cognitive behavioral therapy with pharmacotherapy.,, 2010, 33,, 687-699,[http:\/\/dx.doi.org\/10.1016\/j.psc.2010. 04.008]. [PMID: 20599140].","journal-title":"Psychiatr Clin North Am"},{"key":"ref=250","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4088\/JCP.11r07356","volume":"73","author":"Bontempo A.","year":"2012","unstructured":"Bontempo A, Panza KE, Bloch MH. J Clin Psychiatry, D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis.,, 2012, 73,, 533-537,[http:\/\/dx.doi.org\/10.4088\/JCP.11r07356]. [PMID: 22579153].","journal-title":"J Clin Psychiatry"},{"key":"ref=251","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1527-3458.2006.00208.x","volume":"12","author":"Hofmann S.G.","year":"2006","unstructured":"Hofmann SG, Pollack MH, Otto MW. CNS Drug Rev, Augmentation treatment of psychotherapy for anxiety disorders with D-cycloserine.,, 2006, 12,, 208-217,[http:\/\/dx.doi.org\/10. 1111\/j.1527-3458.2006.00208.x]. [PMID: 17227287].","journal-title":"CNS Drug Rev"},{"key":"ref=252","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.biopsych.2012.02.033","volume":"71","author":"de Kleine R.A.","year":"2012","unstructured":"de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A. Biol Psychiatry, A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder.,, 2012, 71,, 962-968,[http:\/\/dx. doi.org\/10.1016\/j.biopsych.2012.02.033]. [PMID: 22480663].","journal-title":"Biol Psychiatry"},{"key":"ref=253","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0006-3223(99)00133-X","volume":"47","author":"D\u2019Souza D.C.","year":"2000","unstructured":"D\u2019Souza DC, Gil R, Cassello K, Morrissey K, Abi-Saab D, White J, Sturwold R, Bennett A, Karper LP, Zuzarte E, Charney DS, Krystal JH. Biol Psychiatry, IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans.,, 2000, 47,, 450-462,[http:\/\/dx.doi.org\/10.1016\/S0006-3223(99)00133-X]. [PMID: 10704956].","journal-title":"Biol Psychiatry"},{"key":"ref=254","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0014-2999(94)90687-4","volume":"257","author":"Quartermain D.","year":"1994","unstructured":"Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH. Eur J Pharmacol, Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention.,, 1994, 257,, 7-12,[http:\/\/dx.doi. org\/10.1016\/0014-2999(94)90687-4]. [PMID: 8082709].","journal-title":"Eur J Pharmacol"},{"key":"ref=255","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0006-8993(93)91239-O","volume":"603","author":"Boje K.M.","year":"1993","unstructured":"Boje KM, Wong G, Skolnick P. Brain Res, Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures.,, 1993, 603,, 207-214,[http:\/\/dx.doi.org\/10. 1016\/0006-8993(93)91239-O]. [PMID: 8096423].","journal-title":"Brain Res"},{"key":"ref=256","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eurpsy.2016.06.011","volume":"40","author":"de Leeuw A.S.","year":"2017","unstructured":"de Leeuw AS, van Megen HJ, Kahn RS, Westenberg HG. Eur Psychiatry, d-cycloserine addition to exposure sessions in the treatment of patients with obsessive-compulsive disorder.,, 2017, 40,, 38-44,[http:\/\/dx.doi.org\/10.1016\/j.eurpsy.2016.06.011]. [PMID: 27837671].","journal-title":"Eur Psychiatry"},{"key":"ref=257","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nature00839","volume":"418","author":"Marsicano G.","year":"2002","unstructured":"Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglg\u00e4nsberger W, Di Marzo V, Lutz B. Nature, The endogenous cannabinoid system controls extinction of aversive memories.,, 2002, 418,, 530-534,[http:\/\/dx.doi.org\/10.1038\/nature00839]. [PMID: 12152079].","journal-title":"Nature"},{"key":"ref=258","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.1210\/en.2010-0285","volume":"151","author":"Evanson N.K.","year":"2010","unstructured":"Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP. Endocrinology, Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling.,, 2010, 151,, 4811-4819,[http:\/\/dx.doi.org\/10.1210\/en.2010-0285]. [PMID: 20702575].","journal-title":"Endocrinology"},{"key":"ref=259","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/npp.2013.51","volume":"38","author":"Abush H.","year":"2013","unstructured":"Abush H, Akirav I. Neuropsychopharmacology, Cannabinoids ameliorate impairments induced by chronic stress to synaptic plasticity and short-term memory.,, 2013, 38,, 1521-1534,[http:\/\/ dx.doi.org\/10.1038\/npp.2013.51]. [PMID: 23426383].","journal-title":"Neuropsychopharmacology"},{"key":"ref=260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2012.12.002","volume":"138","author":"Micale V.","year":"2013","unstructured":"Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. Pharmacol Ther, Endocannabinoid system and mood disorders: priming a target for new therapies.,, 2013, 138,, 18-37,[http:\/\/dx. doi.org\/10.1016\/j.pharmthera.2012.12.002]. [PMID: 23261685].","journal-title":"Pharmacol Ther"},{"key":"ref=261","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.1016\/S1516-4446(12)70057-0","volume":"34","author":"Schier A.R.","year":"2012","unstructured":"Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Rev Bras Psiquiatr, Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.,, 2012, 34,, S104-S110,[http:\/\/dx.doi.org\/10.1016\/S1516-4446(12)70057-0]. [PMID: 22729452].","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=262","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsycho.2014.10.010","volume":"104","author":"Papini S.","year":"2015","unstructured":"Papini S, Sullivan GM, Hien DA, Shvil E, Neria Y. Biol Psychol, Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical research.,, 2015, 104,, 8-18,[http:\/\/dx.doi.org\/10.1016\/j. biopsycho.2014.10.010]. [PMID: 25448242].","journal-title":"Biol Psychol"},{"key":"ref=263","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s13311-015-0387-1","volume":"12","author":"Blessing E.M.","year":"2015","unstructured":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Neurotherapeutics, Cannabidiol as a potential treatment for anxiety disorders.,, 2015, 12,, 825-836,[http:\/\/dx.doi.org\/10.1007\/ s13311-015-0387-1]. [PMID: 26341731].","journal-title":"Neurotherapeutics"},{"key":"ref=264","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.2174\/138161212802884627","volume":"18","author":"Martinotti G.","year":"2012","unstructured":"Martinotti G, Di Iorio G, Sepede G, De Berardis D, De Risio L, Di Giannantonio M. Curr Pharm Des, Cannabis use and psychosis: theme introduction.,, 2012, 18,, 4991-4998,[http:\/\/dx. doi.org\/10.2174\/138161212802884627]. [PMID: 22716149].","journal-title":"Curr Pharm Des"},{"key":"ref=265","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s12325-016-0468-5","volume":"34","author":"Rutrick D.","year":"2017","unstructured":"Rutrick D, Stein DJ, Subramanian G, Smith B, Fava M, Hasler G, Cha JH, Gasparini F, Donchev T, Ocwieja M, Johns D, Gomez-Mancilla B. Adv Ther, Mavoglurant augmentation in OCD patients resistant to selective serotonin reuptake inhibitors: a proof-of-concept, randomized, placebo-controlled, phase 2 study.,, 2017, 34,, 524-541,[http:\/\/dx.doi.org\/10.1007\/s12325-016-0468-5]. [PMID: 28044255].","journal-title":"Adv Ther"},{"key":"ref=266","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3956(03)00077-3","volume":"38","author":"Fux M.","year":"2004","unstructured":"Fux M, Benjamin J, Nemets B. J Psychiatr Res, A placebo-controlled cross-over trial of adjunctive EPA in OCD.,, 2004, 38,, 323-325,[http:\/\/dx.doi.org\/10.1016\/S0022-3956(03)00077-3]. [PMID: 15003438].","journal-title":"J Psychiatr Res"},{"key":"ref=267","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.psychres.2011.01.019","volume":"189","author":"Sayyah M.","year":"2011","unstructured":"Sayyah M, Boostani H, Pakseresht S, Malayeri A. Psychiatry Res, A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder.,, 2011, 189,, 403-406,[http:\/\/dx.doi.org\/ 10.1016\/j.psychres.2011.01.019]. [PMID: 21329988].","journal-title":"Psychiatry Res"},{"key":"ref=268","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2584","volume":"32","author":"Arabzadeh S.","year":"2017","unstructured":"Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z, Akhondzadeh S. Hum Psychopharmacol, L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study.,, 2017, 32,, 403-,[http:\/\/dx.doi.org\/10.1002\/hup.2584]. [PMID: 28485008].","journal-title":"Hum Psychopharmacol"},{"key":"ref=269","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.153.9.1219","volume":"153","author":"Fux M.","year":"1996","unstructured":"Fux M, Levine J, Aviv A, Belmaker RH. Am J Psychiatry, Inositol treatment of obsessive-compulsive disorder.,, 1996, 153,, 1219-1221,[http:\/\/dx.doi.org\/10.1176\/ajp.153.9.1219]. [PMID: 8780431].","journal-title":"Am J Psychiatry"},{"key":"ref=270","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/11635850-000000000-00000","volume":"26","author":"Askari N.","year":"2012","unstructured":"Askari N, Moin M, Sanati M, Tajdini M, Hosseini SM, Modabbernia A, Najand B, Salimi S, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. CNS Drugs, Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.,, 2012, 26,, 883-892,[http:\/\/dx.doi.org\/10.2165\/11635850-000000000-00000]. [PMID: 22873680].","journal-title":"CNS Drugs"},{"key":"ref=271","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(00)00065-1","volume":"10","author":"Dannon P.N.","year":"2000","unstructured":"Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Eur Neuropsychopharmacol, Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial.,, 2000, 10,, 165-169,[http:\/\/dx.doi. org\/10.1016\/S0924-977X(00)00065-1]. [PMID: 10793318].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=272","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","volume":"47","author":"Ghaleiha A.","year":"2013","unstructured":"Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, Ashrafi M, Hajiaghaee R, Akhondzadeh S. J Psychiatr Res, Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.,, 2013, 47,, 175-180,[http:\/\/dx.doi.org\/10.1016\/j. jpsychires.2012.09.015]. [PMID: 23063327].","journal-title":"J Psychiatr Res"},{"key":"ref=273","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","volume":"228","author":"Haghighi M.","year":"2013","unstructured":"Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, Afshar H, Holsboer-Trachsler E, Brand S. Psychopharmacology (Berl), In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).,, 2013, 228,, 633-640,[http:\/\/dx.doi. org\/10.1007\/s00213-013-3067-z]. [PMID: 23525525].","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=274","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1055\/s-0043-120268","volume":"51","author":"Modarresi A.","year":"2018","unstructured":"Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L. Pharmacopsychiatry, Memantine augmentation improves symptoms in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a randomized controlled trial.,, 2018, 51,, 263-269,Epub ahead of print [http:\/\/dx.doi.org\/10.1055\/s-0043-120268]. [PMID: 29100251].","journal-title":"Pharmacopsychiatry"},{"key":"ref=275","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","volume":"29","author":"Sarris J.","year":"2015","unstructured":"Sarris J, Oliver G, Camfield DA, Dean OM, Dowling N, Smith DJ, Murphy J, Menon R, Berk M, Blair-West S, Ng CH. CNS Drugs, Menon.; R.; Berk, M.; Blair-West, S.; Ng, C.H. N-acetyl cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study.,, 2015, 29,, 801-809,[http:\/\/dx.doi.org\/10.1007\/s40263-015-0272-9]. [PMID: 26374743].","journal-title":"CNS Drugs"},{"key":"ref=276","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","volume":"32","author":"Afshar H.","year":"2012","unstructured":"Afshar H, Roohafza H, Mohammad-Beigi H, Haghighi M, Jahangard L, Shokouh P, Sadeghi M, Hafezian H. J Clin Psychopharmacol, N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.,, 2012, 32,, 797-803,[http:\/\/dx.doi.org\/ 10.1097\/JCP.0b013e318272677d]. [PMID: 23131885].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=277","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","volume":"41","author":"Paydary K.","year":"2016","unstructured":"Paydary K, Akamaloo A, Ahmadipour A, Pishgar F, Emamzadehfard S, Akhondzadeh S. J Clin Pharm Ther, N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.,, 2016, 41,, 214-219,[http:\/\/dx.doi.org\/10.1111\/jcpt.12370]. [PMID: 26931055].","journal-title":"J Clin Pharm Ther"},{"key":"ref=278","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.4088\/JCP.16m11101","volume":"78","author":"Costa D.L.C.","year":"2017","unstructured":"Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. J Clin Psychiatry, Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder.,, 2017, 78,, e766-e773,[http:\/\/dx.doi.org\/10.4088\/JCP. 16m11101]. [PMID: 28617566].","journal-title":"J Clin Psychiatry"},{"key":"ref=279","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1176\/ajp.150.5.819","volume":"150","author":"Grady T.A.","year":"1993","unstructured":"Grady TA, Pigott TA, L\u2019Heureux F, Hill JL, Bernstein SE, Murphy DL. Am J Psychiatry, Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.,, 1993, 150,, 819-821,[http:\/\/dx.doi.org\/10.1176\/ ajp.150.5.819]. [PMID: 8480832].","journal-title":"Am J Psychiatry"},{"key":"ref=280","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.150.4.647","volume":"150","author":"McDougle C.J.","year":"1993","unstructured":"McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR, Price LH. Am J Psychiatry, Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.,, 1993, 150,, 647-649,[http:\/\/dx.doi.org\/10.1176\/ajp.150.4.647]. [PMID: 8465885].","journal-title":"Am J Psychiatry"},{"key":"ref=281","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/15622970309167908","volume":"4","author":"Hollander E.","year":"2003","unstructured":"Hollander E, Kaplan A, Stahl SM. World J Biol Psychiatry, A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder.,, 2003, 4,, 30-34,[http:\/\/dx.doi.org\/10. 3109\/15622970309167908]. [PMID: 12582975].","journal-title":"World J Biol Psychiatry"},{"key":"ref=282","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpsychires.2008.10.007","volume":"43","author":"Greenberg W.M.","year":"2009","unstructured":"Greenberg WM, Benedict MM, Doerfer J, Perrin M, Panek L, Cleveland WL, Javitt DC. J Psychiatr Res, Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults.,, 2009, 43,, 664-670,[http:\/\/dx.doi.org\/10.1016\/j.jpsychires. 2008.10.007]. [PMID: 19046587].","journal-title":"J Psychiatr Res"},{"key":"ref=283","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004714-199106000-00005","volume":"11","author":"McDougle C.J.","year":"1991","unstructured":"McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. J Clin Psychopharmacol, A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.,, 1991, 11,, 175-184,[http:\/\/dx. doi.org\/10.1097\/00004714-199106000-00005]. [PMID: 1820757].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=284","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.euroneuro.2008.01.006","volume":"18","author":"Amiaz R.","year":"2008","unstructured":"Amiaz R, Fostick L, Gershon A, Zohar J. Eur Neuropsychopharmacol, Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study.,, 2008, 18,, 455-461,[http:\/\/dx. doi.org\/10.1016\/j.euroneuro.2008.01.006]. [PMID: 18353618].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=285","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","volume":"76","author":"Pittenger C.","year":"2015","unstructured":"Pittenger C, Bloch MH, Wasylink S, Billingslea E, Simpson R, Jakubovski E, Kelmendi B, Sanacora G, Coric V. J Clin Psychiatry, Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial.,, 2015, 76,, 1075-1084,[http:\/\/dx.doi.org\/10.4088\/JCP.14m09123]. [PMID: 26214725].","journal-title":"J Clin Psychiatry"},{"key":"ref=286","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1017\/S1092852900014292","volume":"11","author":"Besiroglu L.","year":"2006","unstructured":"Besiroglu L, Agargun MY, Ozbebit O, Aydin A. CNS Spectr, A discrimination based on autogenous versus reactive obsessions in obsessive-compulsive disorder and related clinical manifestations.,, 2006, 11,, 179-186,[http:\/\/dx.doi.org\/10.1017\/ S1092852900014292]. [PMID: 16575374].","journal-title":"CNS Spectr"},{"key":"ref=287","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0005-7967(01)00101-2","volume":"41","author":"Lee H.J.","year":"2003","unstructured":"Lee HJ, Kwon SM. Behav Res Ther, Two different types of obsession: autogenous obsessions and reactive obsessions.,, 2003, 41,, 11-29,[http:\/\/dx.doi.org\/10.1016\/S0005-7967(01)00101-2]. [PMID: 12488117].","journal-title":"Behav Res Ther"},{"key":"ref=288","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.janxdis.2004.10.001","volume":"19","author":"Lee H.J.","year":"2005","unstructured":"Lee HJ, Telch MJ. J Anxiety Disord, Autogenous\/reactive obsessions and their relationship with OCD symptoms and schizotypal personality features.,, 2005, 19,, 793-805,[http:\/\/dx.doi.org\/ 10.1016\/j.janxdis.2004.10.001]. [PMID: 16076425].","journal-title":"J Anxiety Disord"},{"key":"ref=289","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1600-0447.2011.01726.x","volume":"124","author":"Besiroglu L.","year":"2011","unstructured":"Besiroglu L, Sozen M, Ozbebit O, Avcu S, Selvi Y, Bora A, Atli A, Unal O, Bulut MD. Acta Psychiatr Scand, The involvement of distinct neural systems in patients with obsessive-compulsive disorder with autogenous and reactive obsessions.,, 2011, 124,, 141-151,[http:\/\/dx.doi.org\/10.1111\/j.1600-0447.2011. 01726.x]. [PMID: 21627621].","journal-title":"Acta Psychiatr Scand"},{"key":"ref=290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075273","volume":"8","author":"Subir\u00e0 M.","year":"2013","unstructured":"Subir\u00e0 M, Alonso P, Segal\u00e0s C, Real E, L\u00f3pez-Sol\u00e0 C, Pujol J, Mart\u00ednez-Zalaca\u00edn I, Harrison BJ, Mench\u00f3n JM, Cardoner N, Soriano-Mas C. PLoS One, Brain structural alterations in obsessive-compulsive disorder patients with autogenous and reactive obsessions.,, 2013, 8,, 141-,[http:\/\/dx.doi.org\/10.1371\/ journal.pone.0075273]. [PMID: 24098688].","journal-title":"PLoS One"},{"key":"ref=291","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1600-0447.2005.00682.x","volume":"113","author":"Rufer M.","year":"2006","unstructured":"Rufer M, Fricke S, Moritz S, Kloss M, Hand I. Acta Psychiatr Scand, Symptom dimensions in obsessive-compulsive disorder: prediction of cognitive-behavior therapy outcome.,, 2006, 113,, 440-446,[http:\/\/dx.doi.org\/10.1111\/j.1600-0447.2005.0 0682.x]. [PMID: 16603035].","journal-title":"Acta Psychiatr Scand"},{"key":"ref=292","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4088\/JCP.v66n1204","volume":"66","author":"Shetti C.N.","year":"2005","unstructured":"Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, Siddequehusen MU, Raghunandanan S. J Clin Psychiatry, Clinical predictors of drug nonresponse in obsessive-compulsive disorder.,, 2005, 66,, 1517-1523,[http:\/\/ dx.doi.org\/10.4088\/JCP.v66n1204]. [PMID: 16401151].","journal-title":"J Clin Psychiatry"},{"key":"ref=293","first-page":"315","volume":"18","author":"Denys D.","year":"2003","unstructured":"Denys D, Burger H, van Megen H, de Geus F, Westenberg H. Int Clin Psychopharmacol, A score for predicting response to pharmacotherapy in obsessive-compulsive disorder.,, 2003, 18,, 315-322,[http:\/\/dx.doi.org\/10.1097\/00004850-200311000-00002]. [PMID: 14571151].","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=294","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1176\/appi.ajp.158.11.1899","volume":"158","author":"Rosario-Campos M.C.","year":"2001","unstructured":"Rosario-Campos MC, Leckman JF, Mercadante MT, Shavitt RG, Prado HS, Sada P, Zamignani D, Miguel EC. Am J Psychiatry, Adults with early-onset obsessive-compulsive disorder.,, 2001, 158,, 1899-1903,[http:\/\/dx.doi.org\/10.1176\/appi.ajp.158. 11.1899]. [PMID: 11691698].","journal-title":"Am J Psychiatry"},{"key":"ref=295","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0005-7967(03)00120-7","volume":"42","author":"Moritz S.","year":"2004","unstructured":"Moritz S, Fricke S, Jacobsen D, Kloss M, Wein C, Rufer M, Katenkamp B, Farhumand R, Hand I. Behav Res Ther, Positive schizotypal symptoms predict treatment outcome in obsessive-compulsive disorder.,, 2004, 42,, 217-227,[http:\/\/dx.doi.org\/ 10.1016\/S0005-7967(03)00120-7]. [PMID: 14975782].","journal-title":"Behav Res Ther"},{"key":"ref=296","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4088\/JCP.v63n1204","volume":"63","author":"Overbeek T.","year":"2002","unstructured":"Overbeek T, Schruers K, Vermetten E, Griez E. J Clin Psychiatry, Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect.,, 2002, 63,, 1106-1112,[http:\/\/dx.doi.org\/10.4088\/JCP.v63n1204]. [PMID: 12523869].","journal-title":"J Clin Psychiatry"},{"key":"ref=297","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hup.2541","volume":"31","author":"Brakoulias V.","year":"2016","unstructured":"Brakoulias V, Starcevic V, Belloch A, Dell\u2019Osso L, Ferr\u00e3o YA, Fontenelle LF, Lochner C, Marazziti D, Martin A, Matsunaga H, Miguel EC, Reddy YC, do Ros\u00e1rio MC, Shavitt RG, Sundar AS, Stein DJ, Viswasam K. Hum Psychopharmacol, International prescribing practices in obsessive-compulsive disorder (OCD).,, 2016, 31,, 319-324,[http:\/\/dx.doi.org\/10. 1002\/hup.2541]. [PMID: 27271200].","journal-title":"Hum Psychopharmacol"},{"key":"ref=298","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","volume":"30","author":"Stewart S.E.","year":"2010","unstructured":"Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, Jenike MA. J Clin Psychopharmacol, A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.,, 2010, 30,, 34-39,[http:\/\/dx.doi.org\/10.1097\/ JCP.0b013e3181c856de]. [PMID: 20075645].","journal-title":"J Clin Psychopharmacol"},{"key":"ref=299","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","volume":"38","author":"Rodriguez C.I.","year":"2013","unstructured":"Rodriguez CI, Kegeles LS, Levinson A, Feng T, Marcus SM, Vermes D, Flood P, Simpson HB. Neuropsychopharmacology, Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.,, 2013, 38,, 2475-2483,[http:\/\/dx.doi.org\/10.1038\/npp.2013.150]. [PMID: 23783065].","journal-title":"Neuropsychopharmacology"},{"key":"ref=300","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.2013.2","volume":"93","author":"Hicks J.K.","year":"2013","unstructured":"Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, Skaar TC, M\u00fcller DJ, Gaedigk A, Stingl JC. Clin Pharmacol Ther, Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.,, 2013, 93,, 402-408,[http:\/\/ dx.doi.org\/10.1038\/clpt.2013.2]. [PMID: 23486447].","journal-title":"Clin Pharmacol Ther"},{"key":"ref=301","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/gtmb.2011.0327","volume":"16","author":"M\u00fcller D.J.","year":"2012","unstructured":"M\u00fcller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, Lieberman JA, Kennedy JL, Richter MA. Genet Test Mol Biomarkers, The AmpliChip\u00ae CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism.,, 2012, 16,, 897-903,[http:\/\/dx.doi.org\/10.1089\/gtmb. 2011.0327]. [PMID: 22775532].","journal-title":"Genet Test Mol Biomarkers"},{"key":"ref=302","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/tpj.2013.12","volume":"14","author":"Brandl E.J.","year":"2014","unstructured":"Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, M\u00fcller DJ, Richter MA. Pharmacogenomics J, Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder.,, 2014, 14,, 176-181,[http:\/\/ dx.doi.org\/10.1038\/tpj.2013.12]. [PMID: 23545896].","journal-title":"Pharmacogenomics J"},{"key":"ref=303","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/pgs.14.83","volume":"15","author":"Zai G.","year":"2014","unstructured":"Zai G, Brandl EJ, M\u00fcller DJ, Richter MA, Kennedy JL. Pharmacogenomics, Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians.,, 2014, 15,, 1147-1157,[http:\/\/dx.doi.org\/ 10.2217\/pgs.14.83]. [PMID: 25084207].","journal-title":"Pharmacogenomics"},{"key":"ref=304","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1073\/pnas.90.6.2542","volume":"90","author":"Ramamoorthy S.","year":"1993","unstructured":"Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V, Blakely RD. Proc Natl Acad Sci USA, Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.,, 1993, 90,, 2542-2546,[http:\/\/dx.doi.org\/10. 1073\/pnas.90.6.2542]. [PMID: 7681602].","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=305","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1046\/j.1471-4159.1996.66062621.x","volume":"66","author":"Heils A.","year":"1996","unstructured":"Heils A, Teufel A, Petri S, St\u00f6ber G, Riederer P, Bengel D, Lesch KP. J Neurochem, Allelic variation of human serotonin transporter gene expression.,, 1996, 66,, 2621-2624,[http:\/\/dx. doi.org\/10.1046\/j.1471-4159.1996.66062621.x]. [PMID: 8632190].","journal-title":"J Neurochem"},{"key":"ref=306","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/ajmg.b.30699","volume":"147B","author":"Bloch M.H.","year":"2008","unstructured":"Bloch MH, Landeros-Weisenberger A, Sen S, Dombrowski P, Kelmendi B, Coric V, Pittenger C, Leckman JF. Am J Med Genet B Neuropsychiatr Genet, Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review.,, 2008, 147B,, 850-858,[http:\/\/dx.doi.org\/ 10.1002\/ajmg.b.30699]. [PMID: 18186076].","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=307","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.biopsych.2009.07.009","volume":"66","author":"Zitterl W.","year":"2009","unstructured":"Zitterl W, Stompe T, Aigner M, Zitterl-Eglseer K, Ritter K, Zettinig G, Hornik K, Asenbaum S, Pirker W, Thau K. Biol Psychiatry, Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.,, 2009, 66,, 1115-1122,[http:\/\/dx.doi.org\/10.1016\/j.biopsych.2009.07.009]. [PMID: 19717141].","journal-title":"Biol Psychiatry"},{"key":"ref=308","doi-asserted-by":"crossref","first-page":"335","DOI":"10.6061\/clinics\/2012(04)06","volume":"67","author":"Corregiari F.M.","year":"2012","unstructured":"Corregiari FM, Bernik M, Cordeiro Q, Vallada H. Clinics (S\u00e3o Paulo), Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.,, 2012, 67,, 335-340,[http:\/\/dx.doi.org\/10.6061\/clinics\/2012(04)06]. [PMID: 22522758].","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"ref=309","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/13651501.2011.653375","volume":"16","author":"Vulink N.C.","year":"2012","unstructured":"Vulink NC, Westenberg HG, van Nieuwerburgh F, Deforce D, Fluitman SB, Meinardi JS, Denys D. Int J Psychiatry Clin Pract, Catechol-O-methyltranferase gene expression is associated with response to citalopram in obsessive-compulsive disorder.,, 2012, 16,, 277-283,[http:\/\/dx.doi.org\/10.3109\/ 13651501.2011.653375]. [PMID: 22414277].","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref=310","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/YCO.0000000000000017","volume":"27","author":"Kariuki-Nyuthe C.","year":"2014","unstructured":"Kariuki-Nyuthe C, Gomez-Mancilla B, Stein DJ. Curr Opin Psychiatry, Obsessive compulsive disorder and the glutamatergic system.,, 2014, 27,, 32-37,[http:\/\/dx.doi.org\/10.1097\/YCO. 0000000000000017]. [PMID: 24270485].","journal-title":"Curr Opin Psychiatry"},{"key":"ref=311","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tics.2011.11.003","volume":"16","author":"Milad M.R.","year":"2012","unstructured":"Milad MR, Rauch SL. Trends Cogn Sci (Regul Ed), Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways.,, 2012, 16,, 43-51,[http:\/\/dx.doi.org\/10.1016\/j.tics.2011.11. 003] [PMID: 22138231].","journal-title":"Trends Cogn Sci (Regul Ed)"},{"key":"ref=312","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/archgenpsychiatry.2009.6","volume":"66","author":"Wendland J.R.","year":"2009","unstructured":"Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG, Ren-Patterson RF, Murphy DL. Arch Gen Psychiatry, A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder.,, 2009, 66,, 408-416,[http:\/\/dx.doi.org\/10. 1001\/archgenpsychiatry.2009.6]. [PMID: 19349310].","journal-title":"Arch Gen Psychiatry"},{"key":"ref=313","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0006-3223(97)00443-5","volume":"43","author":"Rosenberg D.R.","year":"1998","unstructured":"Rosenberg DR, Keshavan MSAEAE. Biol Psychiatry, Bennett Research Award. Toward a neurodevelopmental model of of obsessive--compulsive disorder.,, 1998, 43,, 623-640,[http:\/\/ dx.doi.org\/10.1016\/S0006-3223(97)00443-5]. [PMID: 9582996].","journal-title":"Biol Psychiatry"},{"key":"ref=314","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.neubiorev.2009.01.003","volume":"33","author":"Huyser C.","year":"2009","unstructured":"Huyser C, Veltman DJ, de Haan E, Boer F. Neurosci Biobehav Rev, Paediatric obsessive-compulsive disorder, a neurodevelopmental disorder? Evidence from neuroimaging.,, 2009, 33,, 818-830,[http:\/\/dx.doi.org\/10.1016\/j.neubiorev.2009.01.003]. [PMID: 19428494].","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=315","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jad.2015.07.035","volume":"186","author":"Gass\u00f3 P.","year":"2015","unstructured":"Gass\u00f3 P, Ortiz AE, Mas S, Morer A, Calvo A, Bargall\u00f3 N, Lafuente A, L\u00e1zaro L. J Affect Disord, Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder.,, 2015, 186,, 284-292,[http:\/\/dx.doi.org\/10.1016\/j.jad.2015.07.035]. [PMID: 26254621].","journal-title":"J Affect Disord"},{"key":"ref=316","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.30","volume":"6","author":"Cappi C.","year":"2016","unstructured":"Cappi C, Brentani H, Lima L, Sanders SJ, Zai G, Diniz BJ, Reis VN, Hounie AG, Concei\u00e7\u00e3o do Ros\u00e1rio M, Mariani D, Requena GL, Puga R, Souza-Duran FL, Shavitt RG, Pauls DL, Miguel EC, Fernandez TV. Transl Psychiatry, Whole-exome sequencing in obsessive-compulsive disorder identifies rare mutations in immunological and neurodevelopmental pathways.,, 2016, 6,, 284-,[http:\/\/dx.doi.org\/10.1038\/tp.2016.30]. [PMID: 27023170].","journal-title":"Transl Psychiatry"},{"key":"ref=317","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12031-015-0697-0","volume":"58","author":"Melo-Felippe F.B.","year":"2016","unstructured":"Melo-Felippe FB, de Salles Andrade JB, Giori IG, Vieira-Fonseca T, Fontenelle LF, Kohlrausch FB. J Mol Neurosci, Catechol-O-methyltransferase gene polymorphisms in specific obsessive-compulsive disorder patients\u2019 subgroups.,, 2016, 58,, 129-136,[http:\/\/dx.doi.org\/10.1007\/s12031-015-0697-0]. [PMID: 26687156].","journal-title":"J Mol Neurosci"},{"key":"ref=318","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/mp.2015.32","volume":"21","author":"Qin H.","year":"2016","unstructured":"Qin H, Samuels JF, Wang Y, Zhu Y, Grados MA, Riddle MA, Greenberg BD, Knowles JA, Fyer AJ, McCracken JT, Murphy DL, Rasmussen SA, Cullen BA, Piacentini J, Geller D, Stewart SE, Pauls D, Bienvenu OJ, Goes FS, Maher B, Pulver AE, Valle D, Lange C, Mattheisen M, McLaughlin NC, Liang KY, Nurmi EL, Askland KD, Nestadt G, Shugart YY. Mol Psychiatry, Whole-genome association analysis of treatment response in obsessive-compulsive disorder.,, 2016, 21,, 270-276,[http:\/\/dx.doi.org\/10.1038\/mp.2015. 32]. [PMID: 25824302].","journal-title":"Mol Psychiatry"},{"key":"ref=319","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1242\/dev.043547","volume":"137","author":"Etheridge L.A.","year":"2010","unstructured":"Etheridge LA, Crawford TQ, Zhang S, Roelink H. Development, Evidence for a role of vertebrate Disp1 in long-range Shh signaling.,, 2010, 137,, 133-140,[http:\/\/dx.doi.org\/10.1242\/dev. 043547]. [PMID: 20023168].","journal-title":"Development"},{"key":"ref=320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.9740\/mhc.2016.01.048","volume":"6","author":"Lister J.F.","year":"2016","unstructured":"Lister JF. Ment Health Clin, Pharmacogenomics: A focus on antidepressants and atypical antipsychotics.,, 2016, 6,, 48-53,[http:\/\/dx.doi.org\/10.9740\/mhc.2016.01.048]. [PMID: 29955447].","journal-title":"Ment Health Clin"},{"key":"ref=321","first-page":"e146","volume":"20","author":"Fagerness J.","year":"2014","unstructured":"Fagerness J, Fonseca E, Hess GP, Scott R, Gardner KR, Koffler M, Fava M, Perlis R, Brennan FX, Lombard J. Am J Manag Care, Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings.,, 2014, 20,, e146-e156,[PMID: 25326929].","journal-title":"Am J Manag Care"},{"key":"ref=322","doi-asserted-by":"crossref","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","volume":"13","author":"Singh A.B.","year":"2015","unstructured":"Singh AB. Clin Psychopharmacol Neurosci, Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report.,, 2015, 13,, 150-156,[http:\/\/dx.doi.org\/10.9758\/cpn.2015.13.2.150]. [PMID: 26243841].","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref=323","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4088\/JCP.12r07917","volume":"74","author":"Russell E.J.","year":"2013","unstructured":"Russell EJ, Fawcett JM, Mazmanian D. J Clin Psychiatry, Risk of obsessive-compulsive disorder in pregnant and postpartum women: a meta-analysis.,, 2013, 74,, 377-385,[http:\/\/dx.doi. org\/10.4088\/JCP.12r07917]. [PMID: 23656845].","journal-title":"J Clin Psychiatry"},{"key":"ref=324","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4088\/JCP.v66n0404","volume":"66","author":"Labad J.","year":"2005","unstructured":"Labad J, Mench\u00f3n JM, Alonso P, Segal\u00e0s C, Jim\u00e9nez S, Vallejo J. J Clin Psychiatry, Female reproductive cycle and obsessive-compulsive disorder.,, 2005, 66,, 428-435,[http:\/\/dx.doi. org\/10.4088\/JCP.v66n0404]. [PMID: 15816784].","journal-title":"J Clin Psychiatry"},{"key":"ref=325","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.comppsych.2007.05.001","volume":"48","author":"Uguz F.","year":"2007","unstructured":"Uguz F, Gezginc K, Zeytinci IE, Karatayli S, Askin R, Guler O, Kir SF, Emul HM, Ozbulut O, Gecici O. Compr Psychiatry, Obsessive-compulsive disorder in pregnant women during the third trimester of pregnancy.,, 2007, 48,, 441-445,[http:\/\/dx.doi.org\/10.1016\/j.comppsych.2007.05.001]. [PMID: 17707252].","journal-title":"Compr Psychiatry"},{"key":"ref=326","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.4088\/JCP.09m05381blu","volume":"71","author":"Forray A.","year":"2010","unstructured":"Forray A, Focseneanu M, Pittman B, McDougle CJ, Epperson CN. J Clin Psychiatry, Onset and exacerbation of obsessive-compulsive disorder in pregnancy and the postpartum period.,, 2010, 71,, 1061-1068,[http:\/\/dx.doi.org\/10.4088\/JCP.09m05381blu]. [PMID: 20492843].","journal-title":"J Clin Psychiatry"},{"key":"ref=327","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.earlhumdev.2011.04.014","volume":"87","author":"Loomans E.M.","year":"2011","unstructured":"Loomans EM, van der Stelt O, van Eijsden M, Gemke RJ, Vrijkotte T, den Bergh BR. Early Hum Dev, Antenatal maternal anxiety is associated with problem behaviour at age five.,, 2011, 87,, 565-570,[http:\/\/dx.doi.org\/10.1016\/j.earlhumdev.2011.04. 014]. [PMID: 21576004].","journal-title":"Early Hum Dev"},{"key":"ref=328","first-page":"25","volume":"58","author":"Sanchez S.E.","year":"2013","unstructured":"Sanchez SE, Puente GC, Atencio G, Qiu C, Yanez D, Gelaye B, Williams MA. J Reprod Med, Risk of spontaneous preterm birth in relation to maternal depressive, anxiety, and stress symptoms.,, 2013, 58,, 25-33,[PMID: 23447915].","journal-title":"J Reprod Med"},{"key":"ref=329","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jcpp.12023","volume":"54","author":"Van Batenburg-Eddes T.","year":"2013","unstructured":"Van Batenburg-Eddes T, Brion MJ, Henrichs J, Jaddoe VW, Hofman A, Verhulst FC, Lawlor DA, Davey Smith G, Tiemeier H. J Child Psychol Psychiatry, Parental depressive and anxiety symptoms during pregnancy and attention problems in children: a cross-cohort consistency study.,, 2013, 54,, 591-600,[http:\/\/dx.doi.org\/10.1111\/jcpp.12023]. [PMID: 23215861].","journal-title":"J Child Psychol Psychiatry"},{"key":"ref=330","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10802-013-9766-4","volume":"42","author":"Leis J.A.","year":"2014","unstructured":"Leis JA, Heron J, Stuart EA, Mendelson T. J Abnorm Child Psychol, Associations between maternal mental health and child emotional and behavioral problems: does prenatal mental health matter?,, 2014, 42,, 161-171,[http:\/\/dx.doi.org\/10.1007\/s10802-013-9766-4]. [PMID: 23748337].","journal-title":"J Abnorm Child Psychol"},{"key":"ref=331","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2014.02.027","volume":"159","author":"Ding X.X.","year":"2014","unstructured":"Ding XX, Wu YL, Xu SJ, Zhu RP, Jia XM, Zhang SF, Huang K, Zhu P, Hao JH, Tao FB. J Affect Disord, Maternal anxiety during pregnancy and adverse birth outcomes: a systematic review and meta-analysis of prospective cohort studies.,, 2014, 159,, 103-110,[http:\/\/dx.doi.org\/10.1016\/j.jad.2014.02.027]. [PMID: 24679397].","journal-title":"J Affect Disord"},{"key":"ref=332","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.comppsych.2013.12.018","volume":"55","author":"Uguz F.","year":"2014","unstructured":"Uguz F, Onder Sonmez E, Sahingoz M, Gokmen Z, Basaran M, Gezginc K, Sonmez G, Kaya N, Yilmaz E, Erdem SS, Dulger HH, Cicekler H, Tasyurek E. Compr Psychiatry, Neuroinflammation in the fetus exposed to maternal obsessive-compulsive disorder during pregnancy: a comparative study on cord blood tumor necrosis factor-alpha levels.,, 2014, 55,, 861-865,[http:\/\/ dx.doi.org\/10.1016\/j.comppsych.2013.12.018]. [PMID: 24480417].","journal-title":"Compr Psychiatry"},{"key":"ref=333","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/acps.12042","volume":"127","author":"Byatt N.","year":"2013","unstructured":"Byatt N, Deligiannidis KM, Freeman MP. Acta Psychiatr Scand, Antidepressant use in pregnancy: a critical review focused on risks and controversies.,, 2013, 127,, 94-114,[http:\/\/dx.doi.org\/10. 1111\/acps.12042]. [PMID: 23240634].","journal-title":"Acta Psychiatr Scand"},{"key":"ref=334","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.genhosppsych.2009.04.003","volume":"31","author":"Yonkers K.A.","year":"2009","unstructured":"Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, Ramin S, Chaudron L, Lockwood C. Gen Hosp Psychiatry, The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.,, 2009, 31,, 403-413,[http:\/\/dx.doi.org\/10.1016\/j.genhosppsych.2009.04. 003]. [PMID: 19703633].","journal-title":"Gen Hosp Psychiatry"},{"key":"ref=335","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1590\/1516-4446-2015-1673","volume":"37","author":"Uguz F.","year":"2015","unstructured":"Uguz F. Rev Bras Psiquiatr, Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach.,, 2015, 37,, 334-342,[http:\/\/dx.doi.org\/10.1590\/1516-4446-2015-1673]. [PMID: 26692431].","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=336","doi-asserted-by":"crossref","first-page":"187","DOI":"10.31887\/DCNS.2010.12.2\/mkellner","volume":"12","author":"Kellner M.","year":"2010","unstructured":"Kellner M. Dialogues Clin Neurosci, Drug treatment of obsessive-compulsive disorder.,, 2010, 12,, 187-197,[PMID: 20623923].","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=337","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.reprotox.2010.04.015","volume":"30","author":"Ellfolk M.","year":"2010","unstructured":"Ellfolk M, Malm H. Reprod Toxicol, Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).,, 2010, 30,, 249-260,[http:\/\/dx.doi.org\/10.1016\/ j.reprotox.2010.04.015]. [PMID: 20447455].","journal-title":"Reprod Toxicol"},{"key":"ref=338","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/YCO.0b013e3283413451","volume":"24","author":"Gentile S.","year":"2011","unstructured":"Gentile S. Curr Opin Psychiatry, Drug treatment for mood disorders in pregnancy.,, 2011, 24,, 34-40,[http:\/\/dx.doi.org\/10.1097\/ YCO.0b013e3283413451]. [PMID: 21088587].","journal-title":"Curr Opin Psychiatry"},{"key":"ref=339","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/AOG.0b013e318220edcc","volume":"118","author":"Malm H.","year":"2011","unstructured":"Malm H, Artama M, Gissler M, Ritvanen A. Obstet Gynecol, Selective serotonin reuptake inhibitors and risk for major congenital anomalies.,, 2011, 118,, 111-120,[http:\/\/dx.doi.org\/10. 1097\/AOG.0b013e318220edcc]. [PMID: 21646927].","journal-title":"Obstet Gynecol"},{"key":"ref=340","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1517\/14740338.2011.583917","volume":"10","author":"Lorenzo L.","year":"2011","unstructured":"Lorenzo L, Byers B, Einarson A. Expert Opin Drug Saf, Antidepressant use in pregnancy.,, 2011, 10,, 883-889,[http:\/\/dx. doi.org\/10.1517\/14740338.2011.583917]. [PMID: 21545242].","journal-title":"Expert Opin Drug Saf"},{"key":"ref=341","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/0004867413492219","volume":"47","author":"Myles N.","year":"2013","unstructured":"Myles N, Newall H, Ward H, Large M. Aust N Z J Psychiatry, Systematic meta-analysis of individual selective serotonin reuptake inhibitor medications and congenital malformations.,, 2013, 47,, 1002-1012,[http:\/\/dx.doi.org\/10.1177\/0004867413492219]. [PMID: 23761574].","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=342","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.4088\/JCP.12r07966","volume":"74","author":"Grigoriadis S.","year":"2013","unstructured":"Grigoriadis S. J Clin Psychiatry, VonderPorten, E.H.; Mamisashvili, L.; Roerecke, M.; Rehm, J.; Dennis, C.L.; Koren, G.; Steiner, M.; Mousmanis, P.; Cheung, A.; Ross, L.E. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence.,, 2013, 74,, e293-e308,[http:\/\/dx.doi.org\/10.4088\/JCP.12r07966]. [PMID: 23656855].","journal-title":"J Clin Psychiatry"},{"key":"ref=343","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/0091270011405524","volume":"52","author":"Klieger-Grossmann C.","year":"2012","unstructured":"Klieger-Grossmann C, Weitzner B, Panchaud A, Pistelli A, Einarson T, Koren G, Einarson A. J Clin Pharmacol, Pregnancy outcomes following use of escitalopram: a prospective comparative cohort study.,, 2012, 52,, 766-770,[http:\/\/dx.doi.org\/10.1177\/ 0091270011405524]. [PMID: 22075232].","journal-title":"J Clin Pharmacol"},{"key":"ref=344","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hup.2265","volume":"27","author":"Bellantuono C.","year":"2012","unstructured":"Bellantuono C, Bozzi F, Orsolini L, Catena-Dell\u2019Osso M. Hum Psychopharmacol, The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review.,, 2012, 27,, 534-539,[http:\/\/dx.doi.org\/10.1002\/hup.2265]. [PMID: 23044635].","journal-title":"Hum Psychopharmacol"},{"key":"ref=345","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0091270010373928","volume":"51","author":"Alwan S.","year":"2011","unstructured":"Alwan S, Reefhuis J, Rasmussen SA, Friedman JM. J Clin Pharmacol, Patterns of antidepressant medication use among pregnant women in a United States population.,, 2011, 51,, 264-270,[http:\/\/dx.doi.org\/10.1177\/0091270010373928]. [PMID: 20663997].","journal-title":"J Clin Pharmacol"},{"key":"ref=346","doi-asserted-by":"crossref","first-page":"194.e1","DOI":"10.1016\/j.ajog.2007.07.036","volume":"198","author":"Andrade S.E.","year":"2008","unstructured":"Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Willy ME, Staffa JA, Platt R. Am J Obstet Gynecol, Use of antidepressant medications during pregnancy: a multisite study.,, 2008, 198,, 194.e1-194.e5,[http:\/\/dx.doi.org\/10.1016\/j.ajog.2007.07. 036]. [PMID: 17905176].","journal-title":"Am J Obstet Gynecol"},{"key":"ref=347","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-clinpsy-032813-153626","volume":"10","author":"Yonkers K.A.","year":"2014","unstructured":"Yonkers KA, Blackwell KA, Glover J, Forray A. Annu Rev Clin Psychol, Antidepressant use in pregnant and postpartum women.,, 2014, 10,, 369-392,[http:\/\/dx.doi.org\/10.1146\/annurev-clinpsy-032813-153626]. [PMID: 24313569].","journal-title":"Annu Rev Clin Psychol"},{"key":"ref=348","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/14740338.2014.869582","volume":"13","author":"Gentile S.","year":"2014","unstructured":"Gentile S. Expert Opin Drug Saf, Tricyclic antidepressants in pregnancy and puerperium.,, 2014, 13,, 207-225,[http:\/\/dx.doi.org\/10. 1517\/14740338.2014.869582]. [PMID: 24383525].","journal-title":"Expert Opin Drug Saf"},{"key":"ref=349","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0890-6238(03)00012-1","volume":"17","author":"K\u00e4ll\u00e9n B.A.","year":"2003","unstructured":"K\u00e4ll\u00e9n BA, Otterblad Olausson P. Reprod Toxicol, Maternal drug use in early pregnancy and infant cardiovascular defect.,, 2003, 17,, 255-261,[http:\/\/dx.doi.org\/10.1016\/S0890-6238(03)00012-1]. [PMID: 12759093].","journal-title":"Reprod Toxicol"},{"key":"ref=350","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.reprotox.2005.11.006","volume":"21","author":"K\u00e4ll\u00e9n B.","year":"2006","unstructured":"K\u00e4ll\u00e9n B, Otterblad Olausson P. Reprod Toxicol, Antidepressant drugs during pregnancy and infant congenital heart defect.,, 2006, 21,, 221-222,[http:\/\/dx.doi.org\/10.1016\/j.reprotox.2005. 11.006]. [PMID: 16406480].","journal-title":"Reprod Toxicol"},{"key":"ref=351","first-page":"978","volume":"44","author":"Udechuku A.","year":"2010","unstructured":"Udechuku A, Nguyen T, Hill R, Szego K. Aust N Z J Psychiatry, Antidepressants in pregnancy: a systematic review.,, 2010, 44,, 978-996,[PMID: 21034181].","journal-title":"Aust N Z J Psychiatry"},{"key":"ref=352","doi-asserted-by":"crossref","first-page":"68","DOI":"10.12703\/P6-68","volume":"6","author":"Seibell P.J.","year":"2014","unstructured":"Seibell PJ, Hollander E. F1000Prime Rep, Management of obsessive-compulsive disorder.,, 2014, 6,, 68-,[http:\/\/dx.doi.org\/10. 12703\/P6-68]. [PMID: 25165567].","journal-title":"F1000Prime Rep"},{"key":"ref=353","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1176\/appi.ajp.2007.06071172","volume":"164","author":"Suri R.","year":"2007","unstructured":"Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Am J Psychiatry, Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth.,, 2007, 164,, 1206-1213,[http:\/\/dx.doi.org\/10.1176\/ appi.ajp.2007.06071172]. [PMID: 17671283].","journal-title":"Am J Psychiatry"},{"key":"ref=354","doi-asserted-by":"crossref","first-page":"e1128","DOI":"10.4088\/JCP.13f08883","volume":"74","author":"Andrade C.","year":"2013","unstructured":"Andrade C. J Clin Psychiatry, Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks.,, 2013, 74,, e1128-e1133,[http:\/\/dx. doi.org\/10.4088\/JCP.13f08883]. [PMID: 24434100].","journal-title":"J Clin Psychiatry"},{"key":"ref=355","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/0269881108099423","volume":"24","author":"Diniz J.B.","year":"2010","unstructured":"Diniz JB, Shavitt RG, Pereira CA, Hounie AG, Pimentel I, Koran LM, Dainesi SM, Miguel EC. J Psychopharmacol (Oxford), Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial.,, 2010, 24,, 297-307,[http:\/\/dx.doi.org\/10.1177\/0269881108099423]. [PMID: 19164490].","journal-title":"J Psychopharmacol (Oxford)"},{"key":"ref=356","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euroneuro.2006.07.002","volume":"17","author":"Skapinakis P.","year":"2007","unstructured":"Skapinakis P, Papatheodorou T, Mavreas V. Eur Neuropsychopharmacol, Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.,, 2007, 17,, 79-93,[http:\/\/dx.doi.org\/10.1016\/j.euroneuro.2006.07.002]. [PMID: 16904298].","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=357","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpedi.160.1.65","volume":"160","author":"Bloch M.H.","year":"2006","unstructured":"Bloch MH, Peterson BS, Scahill L, Otka J, Katsovich L, Zhang H, Leckman JF. Arch Pediatr Adolesc Med, Adulthood outcome of tic and obsessive-compulsive symptom severity in children with Tourette syndrome.,, 2006, 160,, 65-69,[http:\/\/dx. doi.org\/10.1001\/archpedi.160.1.65]. [PMID: 16389213].","journal-title":"Arch Pediatr Adolesc Med"},{"key":"ref=358","year":"2013","unstructured":". Arch Pediatr Adolesc Med, ,National Institute for Health and Care Excellence, 2013, 160,, 65-,"},{"key":"ref=359","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jad.2016.04.035","volume":"200","author":"Poppe C.","year":"2016","unstructured":"Poppe C, M\u00fcller ST, Greil W, Walder A, Grohmann R, St\u00fcbner S. J Affect Disord, Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.,, 2016, 200,, 89-96,[http:\/\/dx.doi.org\/10.1016\/j.jad.2016.04.035]. [PMID: 27130958].","journal-title":"J Affect Disord"},{"key":"ref=360","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"Bandelow B.","year":"2012","unstructured":"Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, M\u00f6ller HJ. Int J Psychiatry Clin Pract, Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care.,, 2012, 16,, 77-84,[http:\/\/dx.doi.org\/10.3109\/13651501. 2012.667114]. [PMID: 22540422].","journal-title":"Int J Psychiatry Clin Pract"},{"key":"ref=361","author":"Koran L.M.","year":"2013","unstructured":"Koran LM, Simpson HB. Guideline Watch (March 2013): Practice Guideline for the Treatment of patients with Obsessive-Compulsive Disorder, ,, 2013, 16,, 77-,","journal-title":"Guideline Watch (March 2013): Practice Guideline for the Treatment of patients with Obsessive-Compulsive Disorder"},{"key":"ref=362","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"Moher D.","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Int J Surg, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.,, 2010, 8,, 336-341,[http:\/\/dx.doi.org\/10. 1016\/j.ijsu.2010.02.007]. [PMID: 20171303].","journal-title":"Int J Surg"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/164649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T16:40:00Z","timestamp":1720543200000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/164649\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":362,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,7,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x16666180813155017","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}